Category: vaccine

  • MIL-OSI Economics: Development Asia: Enhancing Vaccine Regulation for Pandemic Preparedness

    Source: Asia Development Bank

    Strengthening regulatory frameworks is critical in ensuring that vaccines are quickly approved and distributed. Using a systematic approach, gaps in key areas of the regulatory system can be identified, prioritized, and effectively addressed through regulatory capacity building and education of regulatory professionals.

    The World Health Organization Global Benchmarking Tool was developed to evaluate regulatory systems objectively and systematically, identify strengths and areas for improvement, guide interventions, and monitor progress in strengthening the regulatory system. Consistent and regular training of national regulators can also complement regulatory systems strengthening efforts by focusing on the identified gaps.

    The diverse and fragmented regulatory environment in Asia and the Pacific calls for regulatory convergence[1] and cooperation to facilitate timely and equitable access in the region. Stable, well-functioning national regulatory authorities in the region listed as WHO Maturity Level 3 and 4 and WHO Listed Authorities, such as those in the People’s Republic of China, India, Indonesia, Republic of Korea, Singapore, Thailand, and Viet Nam, could foster regional regulatory cooperation and serve as reference agencies for lower-resourced regulatory agencies.

    Such cooperation could be facilitated by formalized processes and relationships such as memoranda of understanding. For example, Singapore’s Health Sciences Authority has adopted a confidence-based regulatory approach that leverages the decisions of established and trusted regulatory agencies through formal recognition mechanisms and has expedited reviews without compromising the robustness of regulatory decisions. This has reduced approval timelines to 90 working days from 270 working days for the Health Sciences Authority’s full evaluation route under its verification evaluation system.

    Confidence-based approaches can be adopted in various stages of the vaccine life cycle. The ASEAN Mutual Recognition Arrangement on Good Manufacturing Practice Inspection enables member states to leverage on the regulatory inspections performed by other member states. It is legally binding for member states to recognize one another’s good manufacturing practice certificates, benchmarked against the international Pharmaceutical Inspection Cooperation Scheme.

    Regulatory cooperation can range from legally-binding mechanisms in the form of mutual recognition agreements and reliance mechanisms to other forms of cooperation such as joint collaborative assessments, report sharing and work sharing. Work sharing can promote mutual learning and the sharing of best practices among participating national regulatory authorities and can encourage regulatory convergence. For industry, the work-sharing model can be commercially attractive, providing simultaneous access to multiple countries and shorten timelines with the consolidation of questions.

    While cooperation on vaccine regulation is still nascent, there are other examples of regulatory cooperative mechanisms. Work sharing is practiced by Access Consortium, comprising the national regulatory authorities of Australia, Canada, Singapore, Switzerland and the United Kingdom. A similar coalition is the Opening Procedures at EMA to Non-EU authorities (OPEN) initiative, led by the EMA, which partners Australia, Brazil, Canada, Japan, Switzerland and WHO in joint assessments. In Asia and the Pacific, the Indo-Pacific Regulatory Strengthening Program, comprising Cambodia, Indonesia, Laos, Myanmar, Papua New Guinea, Thailand, and Viet Nam, and supported by Australia, successfully expedited approval of the antimalarial tafenoquine in Thailand in 2019 in its joint review.

    While the work-sharing model has its advantages, the following points also need to be considered:

    • Participating national regulatory authorities may have different priority drug lists and approval timelines.
    • Participating national regulatory authorities may have different technical requirements.
    • Lack of clarity in regulatory decisions could impact company filing strategies.

    Convergence of regulatory requirements can further contribute to successful work-sharing collaborations. One way to incentivize the alignment of key regulatory requirements is the creation of a consensus on indicators that measure overall efficiency of the work-sharing pathway, which participating countries can jointly work towards. Regional regulatory convergence efforts include the APEC Action Plan on Vaccination Across the Life-Course, which sets key policy targets to achieve by 2030. Priorities for alignment include post-approval change management, labeling, and packaging.

    MIL OSI Economics

  • MIL-OSI Economics: Development Asia: Building Sustainable Vaccine Manufacturing Practices in Lower-Resourced Settings

    Source: Asia Development Bank

    Vaccines are inherently labile biologicals that require complex manufacturing and handling processes. Vaccine manufacturing requires multiple considerations, such as technical expertise, production capabilities, market demand, and stringent regulatory requirements. Underpinning these considerations is the need for sustainable funding. Vaccine manufacturing is a capital-intensive endeavor with facilities and equipment costing up to $700 million. This excludes the costs of product development, licensing, regulatory, and overhead costs, clubbed with a significant risk of development failure and unprofitability. Because of the high investments needed, there are often conflicting interests between commercial drivers and public health needs. The COVAX manufacturing task force highlighted key prerequisites for vaccine manufacturing to address future pandemic responses. These include a wide range of efforts, including upgrading manufacturing facilities to international standards, expanding the vaccine manufacturing workforce and regulatory capabilities, and enabling technology transfer.

    Maintaining quality throughout the process of vaccine production to delivery is paramount. As it involves many upstream and downstream processes, vaccine manufacturing demands a robust quality management system to ensure an uninterrupted supply of raw materials, consumables, current Good Manufacturing Practice-compliant facilities, and state-of-the-art equipment. Optimizing the scale-up of production, validation, and prompt resolution of technical issues are important to address when expanding the production capacity. The complexity of production is further constrained by vaccine lability, with many vaccines requiring cold chain maintenance during transportation and storage, some at very low temperatures. In addition, supply chain networks for manufacturing and packaging processes spread across different countries add to the complexity of producing consistently good quality batches of these susceptible biological products.

    From an economic perspective, investing in or scaling up vaccine manufacturing capacity has limited utility without sustainable demand. Overall vaccine demand depends on several factors: i) private, public, and donor market demands; ii) disease prevalence; iii) vaccine effectiveness and safety; iv) trust in the government and health system; and v) social norms, such as social influence, vaccination decisions of peers and vaccine free-riding behavior. For example, Gavi, the Global Vaccine Alliance, provides data on forecasting vaccine demand to assist stakeholders in understanding the vaccine market needs. On the supply side, health systems must also have adequate facility readiness to effectively deliver the vaccines.

    During the COVID-19 pandemic, expedited regulatory approvals were crucial for the rapid development, manufacturing, and delivery of vaccines. However, prior to the pandemic, fragmented regulatory requirements, complex quality control standards, and the lack of a central monitoring and coordinating system to manage capacity had hampered vaccine manufacturing efforts.

    Setting up sustainable vaccine manufacturing capabilities also depends on issues around intellectual property rights of the vaccines. The current Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) established by the World Trade Organization grants disproportionate market power to the bigger developers and manufacturers and leads to market oligopoly, further increasing the barrier of entry for smaller manufacturers. While technology transfer as a method of collaboration is proposed to improve efficiency in manufacturing, it requires extensive and transparent knowledge sharing and active support from the original manufacturers to reproduce the original vaccines with acceptable variations. This entire technology transfer process may take from 18 months up to 30 months as it involves a wide range of activities and expertise, including specialized skills, documentation, laboratory technicians, and regulation registration. In public health emergencies where it is essential to ramp up vaccine production, this timeline delays access to life-saving vaccines.

    Vaccine manufacturing also has a profound impact on the environment. Vaccine packaging material, which is essential for transport and storage, can raise costs including disposal expenses. There is a significant increase in glass, plastic, and rubber residues from vaccine containers as well. Combined with the added waste from the process of vaccination, such as needles and syringes that are often non-biodegradable, vaccine manufacturing greatly affects the environment.

    MIL OSI Economics

  • MIL-OSI Economics: Development Asia: Ensuring Sustainable, Locally Relevant Vaccine R&D in Resource-Limited Settings

    Source: Asia Development Bank

    Decisions on vaccine platform choice should be context-specific.

    Various vaccine technologies or platforms are available to help the body defend against pathogens (Table 1). While mRNA-based vaccines were the fastest to be developed and the most effective against SARS-CoV-2, the technology is not a solution for all pathogens. Each vaccine platform has its advantages and limitations, and choosing one depends on factors such as the pathogen, immune response, outbreak situation, cost, and ease of manufacturing.

    The understanding of how the human body defends against different pathogens often guides vaccine technology selection. The two major protective, vaccine-induced immune components include: 1) neutralizing antibodies in the blood that can block infection and 2) immune T cells that kill infected cells. For example, the immune system combats bacterial infections through T-cell-dependent antibodies targeting the outer bacterial polysaccharide coating. As a result, most bacterial vaccines use polysaccharide conjugate vaccine technologies.

    Tackling pandemic versus endemic pathogens requires vastly different vaccine development considerations. During a pandemic, rapid vaccine development technologies, such as mRNA, are critical. However, for vaccines against endemic pathogens, priorities may shift to long-term immunity and cost-effectiveness. When developing vaccines in or for populations in low-resource settings, cost and manufacturing complexity are key considerations. Furthermore, up-to-date knowledge of the major circulating pathogen strains—both locally and globally—and their associated epidemiology should inform vaccine development.

    Investment in a range of vaccine platforms is critical for maximizing success.

    As countries tackle a vast range of emerging infectious diseases, experts recommend judicious R&D investments in a variety of platforms, as well as innovations in manufacturing. The “portfolio approach” by the Coalition for Epidemic Preparedness Innovations (CEPI) is a case in point. It refers to the deliberate investment in a diverse range of vaccine platforms. Portfolio diversification enhances overall success by ensuring that different platforms do not share the same features and risks of failure.

    Investment in early-stage R&D is instrumental for understanding how vaccine candidates provide protection and for generating evidence to support early go/no-go decisions in vaccine development. All vaccine R&D investments require a comprehensive assessment to evaluate market demand, barriers to access, and expected public health impact. For example, GAVI’s vaccine investment analysis framework aims to understand and capture the full value of vaccines, including social, economic, and population health benefits.

    CEPI’s 100-day mission proposes to build a global vaccine library to promote coordinated investments and a global collaborative network for rapid content sharing. This initiative aims to build a library of vaccine prototypes and incorporate AI tools to forecast virus variants for high-priority diseases before their emergence.

    Accelerating vaccine development requires multi-stakeholder effort.

    The COVID-19 pandemic highlighted the possibility of drastically shrinking clinical development timelines by combining clinical trial phases and using adaptive trial designs. The use of immune correlates of protection (CoP)—i.e., immune parameters responsible for vaccine-induced protection—also enabled the rapid licensure of several COVID-19 vaccines. This was achieved through bridging studies, where immunology results from completed clinical trials were extrapolated to different populations. Fundamental research on high-priority pathogens is therefore crucial for establishing and validating CoP for future pandemic pathogens. Newer methods, such as controlled human challenge models, offer further potential to provide rapid insights into protection and safety.

    Regulatory agility during the pandemic facilitated the expedited development of safe and high-quality vaccines. Similarly, regional and global collaboration in sharing manufacturing processes and vaccine safety and efficacy data further accelerated vaccine R&D. Therefore, continued data sharing, harmonization of regulatory requirements and resolving intellectual property issues will lead to faster availability of new vaccines during emergencies.

    Limited infrastructure, funding, technical expertise, operational and manpower limitations currently hamper trials in resource-limited countries. Equitable vaccine access may be facilitated through international public-private partnerships in vaccine development and technology transfer. Understanding the magnitude and extent of knowledge and expertise gaps in these countries is important for guiding capacity building initiatives.

    Affordability dictates the success of vaccine development programs in resource-limited countries.

    Innovative strategies are essential in ensuring financial sustainability of vaccine R&D in lower-resourced countries. Design and discovery of new and improved vaccine technologies usually require decades of investment in basic scientific research, which is mostly sustainable in high-resource settings. To level the playing field, initiatives such as the WHO mRNA transfer hub and private and philanthropic joint ventures like Hilleman laboratories are working to make new vaccine technologies more accessible to lower-resource countries through technology transfer mechanisms.

    Additionally, vaccine clinical trials require significant financial investments for setting up infrastructure, capacity development and clinical trial implementation. As a solution, WHO recently set up the Global Clinical Trials Forum to strengthen the clinical trial ecosystem in the Global South and promote domestic financing of clinical trials.

    Table 1: Major Vaccine Platforms and Considerations for Development in Resource Constrained Settings

    MIL OSI Economics

  • MIL-OSI Australia: Local outbreak of measles in Victoria

    Source: Government of Victoria 3

    Key messages

    • An outbreak of measles has been identified in Victoria, after two new cases were reported who likely acquired their infection in metropolitan Melbourne. These cases have had no history of overseas travel or known contact with other cases of measles.
    • These cases were infectious at multiple locations around Melbourne and Greater Bendigo. People who have attended a listed exposure site during the specified dates and times should monitor for symptoms of measles and follow the instructions below.
    • Measles is a highly infectious viral illness that can spread from person-to-person and potentially lead to serious health complications including pneumonia and brain inflammation (encephalitis).
    • Anyone who develops symptoms of measles should seek medical care and testing for measles. Wear a face mask and call ahead to make sure you can be isolated from others.
    • Healthcare professionals should be alert for measles in patients with fever and rash, particularly those who have recently returned from overseas or attended a listed exposure site during the specified period.
    • Clinicians should also consider measles in people with compatible symptoms who have spent time in metropolitan Melbourne in the prior 7 to 18 days.
    • Suspected cases should be tested, advised to isolate, and notified to the Department of Health immediately by calling 1300 651 160.
    • All Victorians are eligible to receive the free measles-mumps-rubella (MMR) vaccine if born during or after 1966. Two doses are required for immunity.
    • Victorians born between 1966 and 1992 may not have received two doses of vaccine. If you are unsure, see an immunisation provider now to ask for an MMR vaccine.
    • Anyone planning overseas travel should make sure they have received appropriate travel vaccinations, including the MMR vaccine. This is especially important for anyone planning on travelling to South and South-East Asia, including Vietnam.

    What is the issue?

    Two new cases of measles have been reported in Victoria that have not travelled overseas, and have no known links to recent cases of measles. These cases were infectious at multiple locations in Greater Bendigo and metropolitan Melbourne. This means there is now local transmission of measles in the community.

    Measles is a highly infectious viral illness that can lead to uncommon but serious complications, such as pneumonia and brain inflammation (encephalitis). There have been 8 cases of measles identified in Victoria in 2025.

    A number of populations in Victoria are susceptible to measles, including anyone who is unvaccinated, infants under 12 months of age, immunocompromised people and adults who were born between 1966 and 1992 who may not have received two MMR vaccines in childhood.

    Any overseas travel could also lead to exposure to measles, with outbreaks reported in multiple countries and regions, including Vietnam, Thailand, India, Africa, Europe and the UK, the Middle East, and the USA.

    Active public exposures sites in Victoria for recent cases are listed in the table below.

    Date Time Location Monitor for onset of symptoms up to
    Wednesday 26 February 2025 12:01am to 12:25am

    The Royal Melbourne Hospital Emergency Department

    300 Grattan St, Parkville VIC 3050

    Sunday 16 March 2025
    Tuesday 25 February 2025 5:20pm to 12:00am (midnight)

    The Royal Melbourne Hospital-Emergency Department

    300 Grattan St, Parkville VIC 3050

    Saturday 15 March 2025
    Tuesday 25 February 2025 11:00am to 12:00pm (mid-day)

    DiagnostiCare Specialist Radiology Clinic

    Unit 46/235 Milleara Rd, Keilor East VIC 3033

    Saturday 15 March 2025
    Tuesday 25 February 2025 10:00am to 11:00am

    Australian Clinical Labs

    Eastbrooke Family Clinic Lincolnville, 493-495 Keilor Road, Niddrie VIC 3042

    Saturday 15 March 2025
    Tuesday 25 February 2025 9:00am to 11:00am

    Eastbrooke Family Clinic Lincolnville

    493-495 Keilor Road, Niddrie VIC 3042

    Saturday 15 March 2025
    Monday 24 February 2025 5:50am to 9:00am

    Bendigo Hospital – Emergency Department

    Bendigo Health, Drought St & Arnold Street, North Bendigo VIC 3550

    Thursday 14 March 2025
    Saturday 22 February 2025 4:30pm to 5:05pm

    Chemist Warehouse Airport West

    Westfield Airport West

    40/29-35 Louis St, Airport West VIC 3042

    Tuesday 12 March 2025
    Saturday 22 February 2025 11:30am to 4:30pm

    Keilor East Leisure Centre Swimming Pool

    84 Quinn Grove, Keilor East VIC 3033

    Tuesday 12 March 2025
    Thursday 20 February 2025 4:30pm to 6:30pm

    Epsom Village

    16-20 Howard St, Epsom VIC 3551

    Monday 10 March 2025
    Thursday 20 February 2025 5:50pm to 6:30pm

    Epsom Village Pizza

    Shop 8/16-20 Howard St, Epsom VIC 3551

    Monday 10 March 2025
    Thursday 20 February 2025 5:20pm to 6:15pm

    Chemist Warehouse Epsom

    S/C 16 to Shops 1 to 3/40 Howard St, Epsom VIC 3551

    Monday 10 March 2025
    Thursday 20 February 2025 5:10pm to 5:45 pm

    Woolworths Epsom

    16/40 Howard St, Bendigo VIC 3550

    Monday 10 March 2025
    Thursday 20 February 2025 4:30pm to 5:45pm

    Aldi Epsom

    182/192 Midland Hwy, Epsom VIC 3551

    Monday 10 March 2025
    Thursday 20 February 2025 12:30pm to 01:05pm

    Coles Bendigo

    Williamson St & Myers St, Bendigo VIC 3550

    Monday 10 March 2025
    Wednesday 19 February 2025 4:00pm to 5:30pm

    Oscar Nails and Beauty

    305a Buckley St, Aberfeldie VIC, 3040

    Sunday 9 March 2025
    Wednesday 19 February 2025 8:30pm to 9:05pm

    Lansell Square

    267 High St, Kangaroo Flat VIC 3555

    Sunday 9 March 2025
    Wednesday 19 February 2025 8:30 pm to 9:05pm

    Coles Lansell Square

    267 – 283 High St, Kangaroo Flat VIC 3555

    Sunday 9 March 2025
    Wednesday 19 February 2025: 4:00pm to 5:00pm

    Highpoint Shopping Center

    120-200 Rosamond Rd, Maribyrnong VIC 3032

    Sunday 9 March 2025
    Wednesday 19 February 2025 4:00pm to 5:00pm

    Timezone Highpoint

    Level 1 Highpoint Shopping Centre 120-200 Rosamund Rd, Maribyrnong VIC 3032

    Sunday 9 March 2025

    Anyone who has attended a listed exposure site during the specified times above should monitor for symptoms and seek medical care if symptoms develop for up to 18 days after the exposure and follow the recommendations below.

    In addition, anyone who presents with signs and symptoms compatible with measles should be tested and notified to the Department of Health immediately. There should be an especially high level of suspicion if they have travelled overseas or visited any of the sites listed above and are unvaccinated or partially vaccinated for measles.

    Who is at risk?

    Anyone born during or since 1966 who does not have documented evidence of having received two doses of a measles-containing vaccine, or does not have documented evidence of immunity, is at risk of measles. This is also known as being susceptible to measles.

    Unvaccinated infants are at particularly high risk of contracting measles. Victorians born between 1966 and 1992 may not have received two doses of vaccine, which are required to provide immunity.

    Young infants, pregnant women and people with a weakened immune system are at increased risk of serious complications from measles.

    Symptoms and transmission

    Symptoms of measles include fever, cough, sore or red eyes (conjunctivitis), runny nose, and feeling generally unwell, followed by a red maculopapular rash. The rash usually starts on the face before spreading down the body. Symptoms can develop between 7 to 18 days after exposure.

    Initial symptoms of measles may be similar to those of COVID-19 and influenza. If a symptomatic person tests negative for COVID-19 and/or influenza but develops a rash, they should be advised to continue isolating and be tested for measles.

    People with measles are considered infectious from 24 hours prior to the onset of initial symptoms until 4 days after the rash appears. Measles is highly infectious and can spread through airborne droplets or contact with nose or throat secretions, as well as contaminated surfaces and objects. The measles virus can stay in the environment for up to 2 hours.

    Figures: Example of a typical measles rash

    Recommendations

    For the general public

    • Anyone who has attended a listed exposure site during the specified date and time should monitor for symptoms and seek medical care if symptoms develop for up to 18 days after the exposure.
    • Anyone who attended a listed exposure site and is not fully vaccinated for measles may be eligible to receive the MMR vaccine if they present within 72 hours (3 days) of exposure. Anyone who is immunocompromised or pregnant and not fully vaccinated for measles should seek medical review if within 6 days of exposure to a measles case.
    • Anyone who develops symptoms of measles should seek medical care and testing for measles. Call the health service beforehand to advise that you may have been exposed to measles and wear a face mask.
    • The measles-mumps-rubella (MMR) vaccine provides safe and effective protection against measles. The MMR vaccine is available for free:
      • on the National Immunisation Program, routinely given at 12 months and 18 months of age.
      • for anyone born during or after 1966 who have not already received two doses of measles-containing vaccine, are unsure of their vaccination status, or do not have evidence of immunity to measles.
      • for young infants aged 6 to 12 months prior to overseas travel to countries where measles is endemic or where outbreaks of measles are occurring. If an infant receives an early dose of MMR vaccine prior to travel, they should still receive routine doses at 12 months and 18 months of age as per the National Immunisation Program schedule.
    • Victorians born between 1966 and 1992 may not have received two doses of vaccine. If you are unsure, see an immunisation provider now to ask for an MMR vaccine. Two doses are required for immunity.
    • Anyone planning overseas travel should make sure they have received appropriate travel vaccinations, including MMR vaccination.

    For health professionals

    • For persons who have attended an exposure site, anyone who is not fully vaccinated for measles may be eligible to receive the MMR vaccine if they present within 72 hours (3 days) of exposure. Anyone who is immunocompromised or pregnant and not fully vaccinated for measles may be eligible to receive normal human immunoglobulin (NHIG) if they present up to 144 hours (6 days) after close exposure to a measles case.
    • Clinicians should be alert for measles in patients presenting with compatible illness if they have travelled overseas or attended a listed exposure site during the specified dates and times and are not fully vaccinated against measles.
    • These new cases now indicate local transmission of measles within Victoria. Clinicians should also consider measles in people with compatible symptoms who have spent time in metropolitan Melbourne in the prior 7 to 18 days.
    • Anyone who presents with signs and symptoms compatible with measles should be tested, isolated and notified to the Department of Health immediately, by calling 1300 651 160 and connecting to the relevant Local Public Health Unit.
    • Discuss the need for polymerase chain reaction (PCR) testing using nose and throat swabs with the Local Public Health Unit (PCR testing for measles does not attract a Medicare rebate).
    • Take blood samples for measles serology in all suspected cases.
    • Minimise the risk of measles transmission within your practice/department/community:
      • avoid keeping patients with fever and rash in shared waiting areas (send to a separate room).
      • if measles is suspected, give the patient a single use, fitted face mask and isolate under airborne precautions until a measles diagnosis can be excluded.
      • leave all rooms that were used to assess the suspected case vacant for at least 30 minutes after the consultation.
      • if returning home, patients should isolate at home until test results are available.
    • Offer MMR vaccine to people born during or after 1966 who do not have documented evidence of receiving two doses of a measles-containing vaccine or documented evidence of immunity.
    • Serology is not required before vaccinating.
    • People who are not Medicare eligible can also receive the free MMR vaccine. Refer to the Australian Immunisation Handbook – MeaslesExternal Linkfor further guidance on immunisation.

    MIL OSI News

  • MIL-OSI USA: N.M. Delegation Demands HHS Secretary Kennedy Take Immediate Action to Contain Measles Outbreak

    US Senate News:

    Source: United States Senator Ben Ray Luján (D-New Mexico)
    Delegation Letter Comes Amid Measles Outbreak in New Mexico and Texas;
    Measles is One of the Most Highly Infectious Diseases and Can Lead to Serious Complications Like Pneumonia, Blindness, Brain Swelling, and Death
    Washington, D.C. – U.S. Senators Ben Ray Luján (D-N.M.) and Martin Heinrich (D-N.M.), and U.S. Representatives Teresa Leger Fernández (D-N.M.), Melanie Stansbury (D-N.M.), and Gabe Vasquez (D-N.M.) wrote to Health and Human Services Secretary Robert F. Kennedy, Jr. demanding immediate action to contain the recent outbreak of measles in New Mexico. Measles, once declared eliminated in the U.S. over two decades ago, has sickened nine individuals in Lea Country.
    “Given the Department of Health and Human Services’ (HHS) important responsibility to stop the spread of infectious diseases, we request that you utilize HHS’ authorities for testing and monitoring and vaccine education and promotion, as well as rehire critical federal employees, to stop the spread of this dangerous infection,” the lawmakers wrote in their letter to Secretary Kennedy.
    The lawmakers urged Secretary Kennedy to maintain regular reporting on measles cases, “States report confirmed measles cases to the Centers for Disease Control and Prevention (CDC) through the National Notifiable Diseases Surveillance System. Previously, measles tracking on the CDC website was consistently updated weekly. These updates are critical for public health officials to effectively track the rapid spread of this life-threatening disease. We urge you to maintain posting updated measles tracking data weekly.”
    Following the firing of federal public health officials, the lawmakers demanded the reinstatement of these officials to contain the outbreak, “Just last Friday, two dozen employees at the CDC charged with training public health laboratory staffers and supporting outbreak response efforts were fired. These firings will worsen outbreaks and ultimately threaten the health of all Americans in the face of the next public health emergency. We urgently request that you reinstate the fired federal health workers to help stop the spread of measles and other infectious diseases.”
    Additionally, to prevent future outbreaks, the lawmakers pressed Secretary Kennedy to support life-saving measles vaccines, “Given that most of the infected individuals are unvaccinated, more must be done to increase vaccination rates against measles. Vaccination rates can and should be increased and therefore we request that HHS launch a national campaign to improve measles vaccination rates to prevent future outbreaks.”
    The text of the letter is here and below:
    Dear Secretary Kennedy,
    We are concerned about the recent outbreak of measles in New Mexico. As of Wednesday, there are nine people with confirmed cases of measles in isolation in Lea County, New Mexico. This news comes as the nearby counties of Gaines, Terry, Lubbock, and Yoakum in Texas have recently reported 90 cases with 16 people hospitalized. Given the Department of Health and Human Services’ (HHS) important responsibility to stop the spread of infectious diseases, we request that you utilize HHS’ authorities for testing and monitoring and vaccine education and promotion, as well as rehire critical federal employees, to stop the spread of this dangerous infection.
    Measles is one of the most highly infectious diseases because the virus can survive in the air for up to 2 hours. Ninety percent of people who are susceptible will become infected if exposed. While many recover, some experience serious complications like pneumonia, blindness, brain swelling, and death.
    Preventing and mitigating outbreaks is only possible through effective disease tracking and communication, an adequate workforce, and vaccination. States report confirmed measles cases to the Centers for Disease Control and Prevention (CDC) through the National Notifiable Diseases Surveillance System. Previously, measles tracking on the CDC website was consistently updated weekly. These updates are critical for public health officials to effectively track the rapid spread of this life-threatening disease. We urge you to maintain posting updated measles tracking data weekly.
    The public health workforce protects community health by tracking disease and communicating with the public about health threats. But on January 29, 2025, the Government Accountability Office (GAO) reported that there are still health care workforce shortages that inhibit the U.S.’s ability to protect and improve the health of American communities. Despite these health care workforce shortages, federal employees have been fired from the CDC, National Institutes of Health (NIH), and Indian Health Service (IHS). Just last Friday, two dozen employees at the CDC charged with training public health laboratory staffers and supporting outbreak response efforts were fired. These firings will worsen outbreaks and ultimately threaten the health of all Americans in the face of the next public health emergency. We urgently request that you reinstate the fired federal health workers to help stop the spread of measles and other infectious diseases.
    Finally, the most effective way to protect people from contracting measles is to increase vaccination rates as quickly as possible. The measles vaccine, which also inoculates against mumps and rubella, has been in use for about 60 years and has consistently been found to be safe and effective. We urge you to keep your commitment to maintain the CDC’s Advisory Committee on Immunization Practices (ACIP) recommendations for vaccination. The ACIP is critical for ensuring safe and effective vaccination practices among American adults and children. The resources provided by the ACIP not only help health care providers make vaccination recommendations to their patients but also empower everyday Americans to make informed decisions about their health. Given that most of the infected individuals are unvaccinated, more must be done to increase vaccination rates against measles. Vaccination rates can and should be increased and therefore we request that HHS launch a national campaign to improve measles vaccination rates to prevent future outbreaks.
    In closing, your action is urgently needed to stop the spread of measles in New Mexico and across America. In order to mitigate the further spread of this life-threatening disease, we urge you to utilize HHS’ authorities and proven outbreak mitigation strategies. Specifically, we are asking that you maintain weekly disease tracking data updates, rehire federal health workers, launch a vaccination promotion campaign against measles and other life-threatening infectious diseases, and trust the recommendations of public health experts, physicians, and scientists.
    Thank you for your attention to this critical matter.
    Sincerely,

    MIL OSI USA News

  • MIL-OSI Asia-Pac: LCQ22: COVID-19 Vaccination Programme

    Source: Hong Kong Government special administrative region

    LCQ22: COVID-19 Vaccination Programme
    LCQ22: COVID-19 Vaccination Programme
    *************************************

         Following is a question by Professor the Hon Chan Wing-kwong and a written reply by the Secretary for Health, Professor Lo Chung-mau, in the Legislative Council today (February 26):Question:     To safeguard public health, the Government is implementing a territory-wide COVID-19 Vaccination Programme (the Vaccination Programme) free of charge for eligible persons. In this connection, will the Government inform this Council:(1) of the respective numbers of received vaccination doses and vaccination rates under the Vaccination Programme in the past two years; among them, the respective numbers of received doses and vaccination rates for initial and booster doses;(2) of the respective numbers of received booster doses and booster vaccination rates in the past two years for various priority groups eligible for free booster vaccination, i.e. (i) older adults aged 50 or above (including those living in residential care homes), (ii) persons aged 18 to 49 years with underlying comorbidities, (iii) persons with immunocompromising conditions aged six months and above, (iv) pregnant women, and (v) healthcare workers;(3) of the financial expenditure incurred by the Government in implementing the Vaccination Programme in each of the past two years;(4) whether it knows the number of deaths due to COVID-19 infection in the past two years, and the number of COVID-19 vaccine doses received by the deceased prior to their death; and(5) since the restoration of normalcy after the pandemic, what measures the Government has put in place to promote COVID-19 vaccination among the public, particularly high-risk groups, in order to effectively prevent COVID-19?Reply:President,     With the ever evolvement of the SARS-CoV-2 virus, the prevention and treatment capacities of the local healthcare system and society as a whole have been enhanced significantly.  COVID-19 has been managed as an upper respiratory tract illness by the Government since early 2023. Despite this, the World Health Organization (WHO) highlights that high-risk persons should receive COVID-19 booster doses at appropriate times to lower the risks of serious illness and death. With reference to the recommendations from the WHO as well as the Scientific Committee on Vaccine Preventable Diseases and the Scientific Committee on Emerging and Zoonotic Diseases (JSC) under the Centre for Health Protection of the Department of Health (DH), the Government is currently providing the JN.1 lineage COVID-19 vaccines for eligible individuals aged six months or above.     As the vast majority of the public had past COVID-19 infection, according to the recommendation of the JSC, the Government has simplified the arrangements for initial vaccination, which replaced the previous three-dose definition for initial vaccination, since August 19, 2024. Under the new arrangement, in general, persons aged five or above (regardless of their history of infection with COVID-19) are considered to have completed initial vaccination by receiving one dose of mRNA COVID-19 vaccine. Persons aged six months to four years who have been infected with COVID-19 are considered to have completed initial vaccination by receiving one dose of mRNA COVID-19 vaccine. For those who have not been infected, they should receive two or three doses of vaccines in accordance with the recommendations of the vaccine manufacturers to be considered as having completed initial vaccination.  In addition, the JSC recommended that high-risk priority groups, including individuals aged 50 or above and those with chronic diseases, should receive a booster dose at least six months after the last dose or COVID-19 infection (whichever is later), regardless of the number of doses received previously, in order to enhance protection.     Between 2023 and 2024, the activity level of SARS-CoV-2 virus followed a cyclical pattern, with minor waves occurring every four to six months. For example, the virus became active in early January 2024 with a positive rate of 6.8 per cent among respiratory specimens, peaking at 16.8 per cent in early March before decreasing to lower levels in June. The subsequent wave peaked at 9.06 per cent from late July to early August before subsiding. As of the week ending on February 8, 2025, the positive rate for COVID-19 testing remained at a low level of 0.46 per cent.  Regarding the monitoring of variant strains, the JN.1 and its descendant lineages were the most prevalent variant strains.     The reply, in consultation with the DH and the Hospital Authority (HA), to the question regarding the COVID-19 Vaccination Programme raised by Professor the Hon Chan Wing-kwong is as follows:(1) As at January 31, 2025, a total of more than 21 million doses of COVID-19 vaccines were administered under the COVID-19 Vaccination Programme. In 2023 and 2024, about 586 000 and about 222 000 doses were administered respectively. The definition for initial vaccination was updated since August 19, 2024. Starting from August 19, 2024, about 61 000 doses of COVID-19 vaccines were administered, including about 1 000 initial doses and about 60 000 booster doses. The estimated proportion of people that completed COVID-19 initial vaccination in Hong Kong is about 94 per cent.(2) According to the recommendation of the JSC, since April 20, 2023, citizens have to declare themselves as priority groups to continue receiving free boosters. Therefore, the DH only maintains records of the actual number of vaccinations for individuals who declared themselves as belonging to a priority group on or after April 20, 2023.     From April 20, 2023 to 2024, around 342 000 booster doses of COVID-19 vaccines were administered for the self-reported priority groups. The vaccination figures broken down by the priority groups are as follows: 

    Self-reported priority group
    Number of booster doses administered

    Persons aged 50 or above and adult residents living in residential care homes
    332 000

    Healthcare workers
    6 000

    Persons aged 18 to 49 years with underlying comorbidities
    3 000

    Persons aged six months or above with immunocompromising conditions
    1 000

    Pregnant women
    Less than 400

    Total
    Around 342 000

    Note: Due to the lack of data on the population size of some priority groups, the vaccination rate cannot be calculated.(3) The expenditure figures of the COVID-19 Vaccination Programme for the 2023-24 and 2024-25 (as at January 31, 2025) were $230 million and $124 million respectively.(4) According to the data of the Deaths Registries, a total of 2 944 cases died of COVID-19 between January 2023 and December 2024, with over 98 per cent involving adults aged 50 or above, and among them, nearly 80 per cent had not received COVID-19 vaccination within six months prior to death. In addition, among those fatal cases with available information, nearly 90 per cent had history of known chronic diseases. The data showed that timely booster doses of COVID-19 vaccines for high-risk persons help lower the risk of severe illness and death.(5) Since the launch of the COVID-19 Vaccination Programme, the Government has set up an online booking system which is available around the clock. Members of the public may make a booking through the system for COVID-19 vaccination at Private Clinic COVID-19 Vaccination Stations, Children Community Vaccination Centre, designated general out-patient clinics under the HA, as well as designated Student Health Service Centres, Maternal and Child Health Centres or Elderly Health Centres under the DH. The Government also provides vaccination for adult residents of residential care homes (RCHs) for the elderly and RCHs for persons with disabilities through outreach services under the Residential Care Home Vaccination Programme.     The Centre for Health Protection has been disseminating health messages on prevention of communicable diseases and maintaining personal and environmental hygiene through various channels, such as TV and radio announcements in the public interest, social media, printed media, Health Education Infoline, media and radio interviews, advertisements on public transport, outdoor and digital media. The messages also cover the COVID-19 Vaccination Programme. The Centre for Health Protection will continue to strengthen relevant publicity and health education through various channels. The DH has also encouraged and assisted the elderly in the community, especially elderly singletons, to receive necessary vaccines including COVID-19 vaccine via district networks, such as District Services and Community Care Teams. District Elderly Community Centres and Neighbourhood Elderly Centres under the Social Welfare Department, District Health Centres (DHCs) and DHC Expresses under the Health Bureau, as well as Elderly Health Centres under the DH, will also provide assistance to the elderly in need to make online bookings for COVID-19 vaccination.       In addition, the HA provides COVID-19 vaccination services at its 18 designated general out-patient clinics, 13 designated specialist out-patient clinics, the Children Community Vaccination Centre located at the Hong Kong Children’s Hospital, as well as its staff vaccination depots. The HA also encourages eligible long-stay patients to receive COVID-19 vaccination to reduce the risk of severe cases and fatalities.

     
    Ends/Wednesday, February 26, 2025Issued at HKT 15:20

    NNNN

    MIL OSI Asia Pacific News

  • MIL-OSI Europe: Answer to a written question – WHO international health regulations and pandemic treaty – E-002841/2024(ASW)

    Source: European Parliament

    The Commission sees the negotiations of the Pandemic Agreement (PA) and the amendments to the International Health Regulations (IHR) as important opportunities to address gaps exposed by COVID-19.

    In line with the negotiating directives (addendum to Council Decision (EU) 2022/451[1]), the Commission, negotiating on behalf of the Union, prioritises prevention, including the One Health approach.

    The aim is to strengthen prevention, preparedness and response (PPPR) to pandemics and other public health emergencies. No PA proposal or agreed amendments to the IHR affect the Member States’ responsibilities for the definition of their health policy and for the organisation and delivery of health services and medical care as enshrined in the Treaty on the Functioning of the EU[2]. Sovereignty stands as a guiding principle in the PA proposal and remains unchanged in the amended IHR.

    No new specific ‘PPPR mechanism’ is foreseen under either instrument. The amended IHR created the Coordinating Financial Mechanism which will support the identification of, and access to financing. Many Commission initiatives support and contribute[3] to PPPR, including participation in the Pandemic Fund.

    The Commission committed EUR 427 million to the Pandemic Fund[4], and the Fund aims at increasing health system resilience and adapting to local contexts, with a One Health approach.

    The Commission has three priorities in the 2022 Global Health Strategy[5]: deliver better health and well-being; strengthen health systems and advance universal health coverage; and prevent and combat health threats, including pandemics, applying a One Health approach.

    • [1] Council Decision (EU) 2022/451 of 3 March 2022 authorising the opening of negotiations on behalf of the European Union for an international agreement on pandemic prevention, preparedness and response, as well as complementary amendments to the International Health Regulations (2005).), OJ L 92, 21.3.2022, p. 1.
    • [2] Article 168(7) of the Treaty on the Functioning of the EU.
    • [3] Gavi, the Vaccine Alliance, GPEI-Global Polio Eradication Initiative, the Global Fund to Fight AIDS, Tuberculosis and Malaria, programmes for health with partner countries and regions.
    • [4] This represents 7.9% of EU commitments to global health development assistance (2021-2027).
    • [5] https://health.ec.europa.eu/internationalcooperation/global-health_en
    Last updated: 25 February 2025

    MIL OSI Europe News

  • MIL-OSI Europe: Answer to a written question – Excess mortality since 2020 – E-002411/2024(ASW)

    Source: European Parliament

    Data on excess mortality in EU/European Economic Area (EEA) countries is collected by the EuroMOMO project and by the Eurostat, the Statistical Office of the EU.

    The EuroMOMO project is a European mortality monitoring activity based on overall mortality, but not cause-specific, supported by the European Centre for Disease Prevention and Control (ECDC) and the World Health Organisation (WHO), and hosted by Statens Serum Institut, Denmark[1].

    The statistical office of the European Union (DG ESTAT) publishes an excess mortality indicator, which is based on data from National Statistical Institutes on weekly deaths on a voluntary basis since April 2020[2].

    In the years 2020-2023 the excess deaths rates correlate with the COVID-19 waves and are inversely correlated with vaccination coverage, as highlighted by the WHO[3].

    The Commission supports ongoing studies on post-COVID and its link to various disease outcomes, such as heart disease, diabetes, cancers, or neural dysfunctions[4].

    The ECDC recommends further immunisation as the most effective measure to protect against severe viral respiratory diseases[5] and scenario modelling has shown that high vaccine uptake at the population level is strongly correlated with reduced disease burden.

    • [1] https://www.euromomo.eu/
    • [2] https://ec.europa.eu/eurostat/statistics-explained/index.php?oldid=509982#Recent_data_on_excess_mortality_in_the_EU
    • [3] https://www.nature.com/articles/s41586-022-05522-2
    • [4] https://research-and-innovation.ec.europa.eu/research-area/health/coronavirus_en
    • [5] https://www.ecdc.europa.eu/en/news-events/acute-respiratory-infections-eueea-epidemiological-update-and-current-public-health-0
    Last updated: 24 February 2025

    MIL OSI Europe News

  • MIL-Evening Report: Falling vaccination rates put children at risk of preventable diseases. Governments need a new strategy to boost uptake

    Source: The Conversation (Au and NZ) – By Peter Breadon, Program Director, Health and Aged Care, Grattan Institute

    Yuri A/Shutterstock

    Child vaccination is one of the most cost-effective health interventions. It accounts for 40% of the global reduction in infant deaths since 1974 and has led to big health gains in Australia over the past two decades.

    Australia has been a vaccination success story. Ten years after we begun mass vaccination against polio in 1956, it was virtually eliminated. Our child vaccination rates have been among the best in the world.

    But after peaking in 2020, child vaccination in Australia is falling. Governments need to implement a comprehensive strategy to boost vaccine uptake, or risk exposing more children to potentially preventable infectious diseases.

    Child vaccination has been a triumph

    Thirty years ago, Australia’s childhood vaccination rates were dismal. Then, in 1997, governments introduced the National Immunisation Program to vaccinate children against diseases such as diphtheria, tetanus, and measles.

    Measures to increase coverage included financial incentives for parents and doctors, a public awareness campaign, and collecting and sharing local data to encourage the least-vaccinated regions to catch up with the rest of the country.

    What followed was a public health triumph. In 1995, only 52% of one-year-olds were fully immunised. By 2020, Australia had reached 95% coverage for one-year-olds and five-year-olds. At this level, it’s difficult even for highly infectious diseases, such as measles, to spread in the community, protecting both the vaccinated and unvaccinated.

    By 2020, 95% of children were vaccinated.
    Drazen Zigic/Shutterstock

    Gaps between regions and communities closed too. In 1999, the Northern Territory’s vaccination rate for one-year-olds was the lowest in the country, lagging the national average by six percentage points. By 2020, that gap had virtually disappeared.

    The difference between vaccination rates for First Nations children and other children also narrowed considerably.

    It made children healthier. The years of healthy life lost due to vaccine-preventable diseases for children aged four and younger fell by nearly 40% in the decade to 2015.

    Some diseases have even been eliminated in Australia.

    Our success is slipping away

    But that success is at risk. Since 2020, the share of children who are fully vaccinated has fallen every year. For every child vaccine on the National Immunisation Schedule, protection was lower in 2024 than in 2020.

    Gaps between parts of Australia are opening back up. Vaccination rates in the highest-coverage parts of Australia are largely stable, but they are falling quickly in areas with lower vaccination.

    In 2018, there were only ten communities where more than 10% of one-year-old children were not fully vaccinated. Last year, that number ballooned to 50 communities. That leaves more areas vulnerable to disease and outbreaks.

    While Noosa, the Gold Coast Hinterland and Richmond Valley (near Byron Bay) have persistently had some of the country’s lowest vaccination rates, areas such as Manjimup in Western Australia and Tasmania’s South East Coast have recorded big declines since 2018.

    Missing out on vaccination isn’t just a problem for children.

    One preprint study (which is yet to be peer-reviewed) suggests vaccination during pregnancy may also be declining.

    Far too many older Australians are missing out on recommended vaccinations for flu, COVID, pneumococcal and shingles. Vaccination rates in aged care homes for flu and COVID are worryingly low.

    What’s going wrong?

    Australia isn’t alone. Since the pandemic, child vaccination rates have fallen in many high-income countries, including New Zealand, the United Kingdom and the United States.

    Globally, in 2023, measles cases rose by 20%, and just this year, a measles outbreak in rural Texas has put at least 13 children in hospital.

    Alarmingly, some regions in Australia have lower measles vaccination than that Texas county.

    The timing of trends here and overseas suggests things shifted, or at least accelerated, during the pandemic. Vaccine hesitancy, fuelled by misinformation about COVID vaccines, is a growing threat.

    This year, vaccine sceptic Robert F. Kennedy Jr was appointed to run the US health system, and Louisiana’s top health official has reportedly cancelled the promotion of mass vaccination.

    In Australia, a recent survey found 6% of parents didn’t think vaccines were safe, and 5% believed they don’t work.

    Those concerns are far more common among parents with children who are partially vaccinated or unvaccinated. Among the 2% of parents whose children are unvaccinated, almost half believe vaccines are not safe for their child, and four in ten believe vaccines didn’t work.

    Other consequences of the pandemic were a spike in the cost of living, and a health system struggling to meet demand. More than one in ten parents said cost and difficulty getting an appointment were barriers to vaccinating their children.

    There’s no single cause of sliding vaccination rates, so there’s no one solution. The best way to reverse these worrying trends is to work on all the key barriers at once – from a lack of awareness, to inconvenience, to lack of trust.

    What governments should do

    Governments should step up public health campaigns that counter misinformation, boost awareness of immunisation and its benefits, and communicate effectively to low-vaccination groups. The new Australian Centre for Disease Control should lead the charge.

    Primary health networks, the regional bodies responsible for improving primary care, should share data on vaccination rates with GPs and pharmacies. These networks should also help make services more accessible to communities who are missing out, such as migrant groups and disadvantaged families.

    State and local governments should do the same, sharing data and providing support to make maternal child health services and school-based vaccination programs accessible for all families.

    Governments can communicate better about the benefits of vaccination.
    Yuri A/Shutterstock

    Governments should also be more ambitious about tackling the growing vaccine divides between different parts of the country. The relevant performance measure in the national vaccination agreement is weak. States must only increase five-year-old vaccination rates in four of the ten areas where it is lowest. That only covers a small fraction of low-vaccination areas, and only the final stage of child vaccination.

    Australia needs to set tougher goals, and back them with funding.

    Governments should fund tailored interventions in areas with the lowest rates of vaccination. Proven initiatives include training trusted community members as “community champions” to promote vaccinations, and pop-up clinics or home visits for free vaccinations.

    At this time of year, childcare centres and schools are back in full swing. But every year, each new intake has less protection than the previous cohort. Governments are developing a new national vaccination strategy and must seize the opportunity to turn that trend around. If it commits to a bold national plan, Australia can get back to setting records for child vaccination.

    Grattan Institute has been supported in its work by government, corporates, and philanthropic gifts. A full list of supporting organisations is published at www.grattan.edu.au.

    Wendy Hu does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment. Grattan Institute has been supported in its work by government, corporates, and philanthropic gifts. A full list of supporting organisations is published at www.grattan.edu.au.

    ref. Falling vaccination rates put children at risk of preventable diseases. Governments need a new strategy to boost uptake – https://theconversation.com/falling-vaccination-rates-put-children-at-risk-of-preventable-diseases-governments-need-a-new-strategy-to-boost-uptake-249591

    MIL OSI AnalysisEveningReport.nz

  • MIL-OSI Global: Measles: A resurgent threat in Canada

    Source: The Conversation – Canada – By Ruchika Gupta, Assistant Professor and Medical Microbiologist, Department of Pathobiology and Lab Medicine, LHSC and Schulich School of Medicine and Dentistry, Western University

    The resurgence of measles in Canada is a stark reminder that we cannot take public health achievements for granted. (CDC and NIAID), CC BY

    In the landscape of public health, few stories are as compelling as the unexpected return of a disease we once thought was conquered. Measles, a highly contagious viral infection formally considered eliminated from Canada in 1998, is making a surprising comeback, challenging our public health systems and communities at large.

    The rising numbers of measles cases are a concern as they represent real people and real risks. The current measles situation in Canada is a public health challenge and a critical moment for awareness and action. From urban centres like Toronto and Montréal to smaller communities across the provinces, an emerging pattern demands attention and understanding.

    Outbreaks in Canada

    Current measles outbreaks in Canada are primarily affecting Ontario and Québec. In Ontario, 57 confirmed cases have been documented in 2025, as of Feb. 13. Meanwhile, Québec is experiencing its second outbreak, with 24 confirmed cases reported this year, as of Feb. 21. An earlier outbreak in Québec involved 51 cases from February to June 2024.

    This resurgence can be attributed to several factors, including declining vaccination rates, international travel reintroducing the virus into Canada and the highly contagious nature of measles.

    Vaccination rates for the measles, mumps and rubella (MMR) vaccine have dropped to approximately 82.5 per cent, a significant decline observed during the COVID-19 pandemic. This reduction has created a population of highly susceptible individuals, undermining community immunity — commonly referred to as herd immunity — which requires a vaccination coverage of 95 per cent to effectively prevent outbreaks.

    How measles spreads

    Measles is also one of the most contagious infectious diseases, with a basic reproduction number (R₀) of 12–18. This means that, in a fully susceptible population, one case of measles can lead to an average of 12–18 secondary cases. For the current outbreak, although the initial source was linked to international travel, the majority of cases are now the result of local transmission within Canada, highlighting the importance of maintaining high vaccination coverage and swift public health interventions.

    Measles is a highly contagious airborne disease that spreads easily through respiratory droplets. When an infected person breathes, coughs or sneezes, they release virus particles into the air. These particles can remain infectious for up to two hours, even after the person has left the area. What makes measles particularly challenging to control is its extended period of contagiousness.

    An infected individual can spread the virus from four days before the characteristic rash appears until four days after its onset. This means people can unknowingly transmit the disease before they even realize they’re infected.

    The virus’s ability to spread before symptoms appear, combined with its long contagious period, makes it difficult to contain outbreaks once they begin. This is why maintaining high vaccination rates across the population is crucial. It’s not just about individual protection, but about safeguarding the entire community, especially those who cannot be vaccinated due to age or medical conditions.

    While anyone who isn’t immune either through vaccination or previous infection can contract measles, certain groups — including pregnant women, immunocompromised patients and unvaccinated children under age five — are at higher risk of complications including pneumonia and brain swelling.

    Protecting individuals and communities

    The measles, mumps and rubella (MMR) vaccine is safe and highly effective, with two doses providing up to 99 per cent protection.
    (Shutterstock)

    The message from health-care providers is clear: vaccination is the most effective way to prevent measles. Here’s what you can do:

    1. Ensure vaccination is up to date: The measles vaccine is typically combined with mumps and rubella (MMR) or with varicella (MMRV). Two doses of the vaccine are 99 per cent effective at preventing infection.
    2. Check your immunization records: If you’re unsure about your vaccination status, consult your health-care provider or check your Personal Immunization Record.
    3. Vaccinate children on schedule: In Ontario, children receive two doses of the measles vaccine before age seven as part of routine vaccinations.
    4. Consider early vaccination for infants: In areas with ongoing outbreaks, infants as young as six months may be eligible for early vaccination. Contact your health-care provider before travel for their advice.
      Plan ahead for travel: If you’re traveling internationally, consult a health-care provider at least six weeks before your trip to review your immunization history.
    5. Be aware of the symptoms: high fever, cough, runny nose, red eyes and a characteristic rash.

    If you suspect you or someone in your family has measles, call your health-care provider before visiting a medical facility. This allows them to take necessary precautions to prevent further spread.

    Vaccination is our most effective tool against measles. The MMR vaccine is safe and highly effective, with two doses providing up to 99 per cent protection. By maintaining high vaccination rates across our communities, we can prevent outbreaks and protect those who can’t be vaccinated due to age or medical conditions. As we navigate this situation, it’s crucial to stay informed and follow public health guidelines. Together, we can work to contain these outbreaks and protect the health of all Canadians.

    The resurgence of measles in Canada is a stark reminder that we cannot take our public health achievements for granted. Vaccination has been one of the most successful public health interventions in history, saving millions of lives. By working together — health-care providers, parents and communities — we can turn the tide on this resurgence and protect our most vulnerable populations from this preventable disease.

    Measles is not just a childhood illness or a simple rash. It’s a serious disease with potentially severe complications. But with vigilance, education and a commitment to vaccination, we can once again push measles to the brink of elimination in Canada. The health of our communities depends on it.

    Ruchika Gupta does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

    ref. Measles: A resurgent threat in Canada – https://theconversation.com/measles-a-resurgent-threat-in-canada-249932

    MIL OSI – Global Reports

  • MIL-OSI Asia-Pac: Toddler and paediatric formulation of JN.1 COVID-19 vaccines to be provided end of month

    Source: Hong Kong Government special administrative region

         The Centre for Health Protection (CHP) of the Department of Health (DH) announced today (February 20) that starting from February 25, the JN.1 vaccine will be provided to infants and children aged 6 months to 11 years, replacing the XBB mRNA vaccine (XBB vaccine) currently in use. The CHP also urges those who have not received the initial dose of the COVID-19 vaccine (including infants and children) to get vaccinated as soon as possible. Those at high risk (particularly the elderly and persons with underlying comorbidities) should receive a booster dose as soon as possible for effective prevention against COVID-19.
     
    Vaccine supply
    ———————
         Given that the predominant strains circulating in Hong Kong are JN.1 and its descendant lineages, the World Health Organization (WHO), and the Scientific Committee on Vaccine Preventable Diseases and the Scientific Committee on Emerging and Zoonotic Diseases under the CHP have recommended the use of JN.1 lineage COVID-19 vaccines earlier.

         In light of the above, the Government has been offering the JN.1 vaccine to persons aged 12 years or above under the COVID-19 Vaccination Programme since November 19 last year and has actively procured the toddler and paediatric JN.1 formulation for infants and children aged 6 months to 11 years. 
         â€‹
         About 6 000 doses of Comirnaty JN.1 toddler and paediatric formulation (around 3 000 doses each) have recently arrived in Hong Kong. After stringent checks and inspections to ensure that the vaccine complies with product specifications and relevant cold-chain standards, Government staff have properly stored the vaccines in validated ultra-low temperature freezers at the temperature specified by the drug manufacturer. The Government will, taking into account future vaccine demand, procure COVID-19 vaccines from suppliers in a timely manner.
     
    Booking and vaccination arrangements
    ——————————————
         Under the Government COVID-19 Vaccination Programme, persons aged 6 months or above can receive free initial dose(s). High-risk priority groups can receive booster doses for free at least six months after the last dose or COVID-19 infection (whichever is later), regardless of the number of doses received previously.

         â€‹High-risk priority groups include:

    older adults aged 50 or above, including those living in residential care homes;
    persons aged 18 to 49 years with underlying comorbidities;
    persons with immunocompromising conditions aged 6 months and above;
    pregnant women; and
    healthcare workers.

     
         Eligible persons may schedule a COVID-19 vaccine appointment via the COVID-19 Vaccination Programme booking system.  Infants and children aged 6 months to 11 years who schedule COVID-19 vaccine appointments on or after February 25 will receive the JN.1 vaccine. Infants and children may receive the COVID-19 vaccine at Hong Kong Children’s Hospital, designated Maternal and Child Health Centres, designated Student Health Service Centres under the DH and designated Private Clinic COVID-19 Community Vaccination Stations. For details of vaccination venues, please refer to the webpage. As mentioned above, the Government has been offering the JN.1 vaccine to persons aged 12 years or above participating in the COVID-19 Vaccination Programme since November 19 last year.
     
         As persons who contract influenza and COVID-19 at the same time would be at a higher risk of severe complications and death, the CHP strongly recommends that high-risk individuals receive seasonal influenza vaccination (SIV) and COVID-19 vaccination booster to reduce risks of serious illness and death. The WHO has also pointed out that high-risk persons should receive booster doses at appropriate times to lower risks of serious illness and death.
     
         For citizens who have not yet received SIV while receiving a COVID-19 vaccine, they can check with vaccination venues for arrangements for influenza vaccination. According to scientific evidence, COVID-19 vaccines and seasonal influenza vaccines can be administered at the same time to provide dual protection.

         Members of the public may visit the CHP’s COVID-19 Vaccination Programme and seasonal influenza webpage for more details.

    MIL OSI Asia Pacific News

  • MIL-OSI United Nations: 20 February 2025 Departmental update Message by the Director of the Department of Immunization, Vaccines and Biologicals at WHO – January/February 2025

    Source: World Health Organisation

    Safeguarding children and adolescents from deadly, yet preventable diseases, such as polio, measles, diphtheria, pertussis, human papillomavirus and tetanus, among others, is the foundation of the Expanded Programme on Immunization (EPI) – saving an estimated 154 million lives and adding over 10 billion years of healthy life. Through strong partnerships and countries’ commitments vaccines have reached every corner of the world and became the single greatest contribution of any health intervention to ensuring babies not only see their first birthdays but continue leading healthy lives into adulthood.

    2025 marks a significant turning point for immunization efforts worldwide.

    Last year, we celebrated the remarkable progress made by the global immunization community since 1974. Each year, new and under-utilized vaccines continue to be introduced in countries. In 2024, four new countries introduced HPV vaccines and 25 adopted the single-dose schedule. Additionally, Niger and Nigeria became the first countries to implement the Men5CV vaccine, a new and affordable meningococcal pentavalent conjugate vaccine, and more than 12 million doses of malaria vaccine reached 17 countries in Africa in 2024 – a pivotal moment in the fight to end malaria.

    The Big Catch-up Initiative, a major vaccine co-financing initiative in collaboration with Gavi and UNICEF, began reaching children left unvaccinated as a result the pandemic. By the end of 2024, an estimated 143 million vaccine doses had been delivered to 36 countries and 10.5 million catch-up doses had already been administered. This year, an additional 104 million doses will be delivered as part of the Big Catch-up, and a new WHO global monitoring dashboard is enabling real-time data tracking to continually strengthen countries strategies and our support to them. The midway point of the Immunization Agenda 2030 is upon us. As we look towards the next five years there are challenges ahead, but the goal is more relevant than ever.

    Five immunization priorities for 2025

    Equity: Reaching Zero-Dose Children

    Vaccine equity remains one of the most urgent global health challenges of our time. While immunization programs have made tremendous progress, millions of children worldwide remain unreached—many of whom are classified as zero-dose children, meaning they have not received a single vaccine. In 2023, 14.5 million children had received no vaccines at all, a sharp increase from 12.9 million in 2019. These children are disproportionately from marginalized communities, including those in conflict zones, remote areas, and urban slums. The gap in coverage not only fuels preventable disease outbreaks but also deepens existing inequalities in health outcomes. Closing this gap requires targeted strategies: improving supply chains, strengthening healthcare infrastructure, and addressing socioeconomic barriers that prevent families from accessing vaccination services. Achieving true equity means ensuring that no child is left behind.

    Outbreaks: The Resurgence of Measles and System Strengthening

    Vaccine-Preventable Disease surveillance is another pillar of global health security. From yellow fever to measles to pneumonia, early detection ensures vaccines reach those who need them most. The alarming rise in measles cases is a stark reminder of result when immunization networks are weakened. Once considered on the path to elimination in many regions, measles is resurging due to gaps in vaccine coverage. This increase is a warning signal that vaccination systems are at risk—delayed campaigns, supply chain disruptions, and weakened trust in health services have created the basis for outbreaks. Strengthening immunization programmes is not just about responding to crises but about intense work to build resilient health systems so those crises are averted in the first place. This means enhancing surveillance, ensuring robust stockpiles of vaccines, training health workers, assuring data systems are in place to drive impact and intensifying essential immunization services. A failure to act decisively now could see other vaccine-preventable diseases following the same dangerous trend.

    Vaccine Confidence: Strengthening Trust Among Communities and Health Workers

    Confidence in vaccines is the backbone of successful immunization efforts. The past few years have exposed both the strengths and vulnerabilities of public trust in vaccines. Misinformation, historical mistrust, and political instability threaten to erode hard-won gains. At the same time, frontline health workers—the trusted faces of vaccination—must be supported with training and resources to confidently engage with communities. Trust must be built through transparency, education, and engagement. Governments, civil society, and the private sector must work together to counter misinformation and misrepresentation, amplify accurate information, and ensure that communities feel empowered, not coerced, in vaccine decision-making.

    New Vaccines: Innovation, Hope, and the Need for Strong Support

    Innovation in vaccines brings immense opportunity for tackling some of the world’s deadliest diseases. The introduction of new vaccines—whether for malaria, RSV, or the next pandemic threat—represents a turning point in public health.  New vaccines are only as impactful as the systems that deliver them. The success of these vaccines hinges not just on their development but on their effective introduction and sustained delivery. This is where our role supporting countries is critical: ensuring that regulatory approvals, financing mechanisms, health system readiness, and community acceptance are in place. Investing in the introduction of these vaccines with the same urgency as their research and development will be key to translating scientific breakthroughs into real-world protection.

    Funding and political challengers

    In January, President Donald Trump signed an Executive Order indicating the United States’ intent to withdraw from WHO. We remain hopeful that the US will reconsider. For decades, the partnership between the US and WHO has been instrumental in achieving historic public health milestones—from the eradication of smallpox to advancing global immunization efforts that have saved millions of lives in the US and around the world. This collaboration has protected Americans at home and abroad through disease surveillance, accelerating scientific progress, and ensuring that life-saving health interventions reach those who need them most, and shutting down outbreaks when they emerge, to limit their impact.

    Global health security is a shared responsibility. Infectious diseases do not respect borders, and the challenges we face—whether responding to outbreaks, developing new vaccines, or ensuring equitable access to healthcare—require international cooperation.

    WHO remains committed to its mission and will continue working with partners to strengthen global health systems. Strong leadership and sustained funding are critical to ensuring immunization programmes remain resilient. However, the political landscape for vaccines is increasingly unpredictable, putting decades of progress at risk.

    Moving Forward Together: A Moment for Global Health Cooperation

    Two upcoming meetings will be pivotal in providing critical guidance for future immunization policies and strategies.

    The Strategic Advisory Group of Experts on Immunization (SAGE) will meet 10-13 March 2025, to advance global immunization policies and priorities. Key discussions will focus on IA2030 progress, pneumococcus vaccine schedules, varicella-zoster vaccination, new vaccine introductions, NITAG strengthening, and global polio eradication policy decisions and mpox updates. The Global Vaccine and Immunization Research Forum (March 25-27, Rio de Janeiro, Brazil) will convene experts from around the world to advance vaccine innovations, sustainable R&D investments, Artificial Intelligence applications to vaccine development, climate-related challenges to immunization, and equitable access to vaccines. Key discussions will highlight Latin American advancements, maternal and new TB vaccines, vaccine role to reduce antimicrobial resistance, and clinical trial innovations for immunization.

    In closing, I want to thank Member States, partners, and all those in the global health community for the resilient commitment and focus on immunization, driven always by high quality evidence, science and impact. Now is the time to remain committed and sharpen our focus so that immunization for all is a reality.

    The world has the tools, knowledge, and capacity to protect future generations through vaccines. Political will and global solidarity are more valuable than ever to make that happen.

    In the words of Dr. Albert Sabin, “A scientist who is also a human being cannot rest while knowledge which might be used to reduce suffering rests on the shelf.” Let’s ensure that decades of progress are not left behind, but are built upon. It is in our hands. It is Humanly Possible.

     —-

    MIL OSI United Nations News

  • MIL-OSI Asia-Pac: Vaccination error being probed

    Source: Hong Kong Information Services

    The Department of Health today said that it is investigating and following up on an incident in which the pneumococcal vaccine was mistakenly administered to two children who were originally scheduled to receive the hepatitis B vaccine at the Tin Shui Wai Maternal & Child Health Centre (MCHC).

    The department has explained and apologised to the parents of the affected children.

    So far, there has been no adverse reaction in the children, and pediatricians have assessed that the incident would not pose a health risk to them.

    In accordance with the regular monitoring mechanism, the Tin Shui Wai MCHC reviewed the vaccination records at the end of the service session on February 17 and found that the number of vaccines administered during the session between 4pm and 5.30pm that day did not correspond to the number of vaccines that should have been administered.

    Seven children should have received the hepatitis B vaccine during the said period.

    Upon review of the number of vaccines administered, it was found that there were two doses of the hepatitis B vaccine left unused and two extra doses of the 15-valent Pneumococcal Conjugate Vaccine (PCV15) that were used. After double-checking the vaccine stock, it was found that two children had been incorrectly immunised with PCV15 during that period.

    A preliminary investigation revealed that the children vaccinated during that period were between one month and seven months old.

    Under the Hong Kong Childhood Immunisation Programme (HKCIP), children receive the first hepatitis B vaccine dose within 24 hours of birth, followed by the second and third doses at one month and six months of age respectively; for PCV15, the first two doses should be administered at two months and four months of age, and a booster dose should be given at 12 months of age.

    The department’s healthcare staff contacted the parents of the seven children to apologise and explain the follow-up action.

    Arrangements have also been made for paediatricians to conduct detailed examinations of the children as soon as possible, to provide them with an additional dose of hepatitis B vaccine at an appropriate time, and to complete three doses of PCV15 vaccinations in accordance with the HKCIP.

    The investigation is ongoing. A preliminary probe indicated that the incident was caused by human error.

    The department has instructed all MCHCs to strengthen the training of frontline staff to ensure that they strictly follow the internal guidelines on checking vaccine and patient information before administering vaccines, and verifying the information with the person accompanying the child for vaccination to prevent the recurrence of similar incidents.

    The department reiterated its sincere apology to those affected. The nursing staff involved in the incident have been suspended from vaccination duties. If any staff misconduct is confirmed, the case will be dealt with in accordance with the established procedures.

    MIL OSI Asia Pacific News

  • MIL-OSI Europe: Answer to a written question – Review and possible revocation of the authorisation for mRNA vaccines in view of new findings – P-002990/2024(ASW)

    Source: European Parliament

    The Commission is in contact with Member States and the European Medicines Agency (EMA) to ensure the continuous quality, safety and efficacy of medicines, including COVID-19 vaccines.

    EMA continuously monitors safety signals and investigates whether there is a causal link between specific batches and reported adverse events. EMA has no evidence so far suggesting that some batches of Comirnaty caused more (or more serious) side effects than other batches[1].

    The quality of every batch is checked by Official Medicines Control Laboratories in Member States and only those complying with the approved quality specifications can be released in the EU.

    Regulators request and collect batch numbers for vaccines to allow them to establish patterns and determine whether suspected side effects are linked to a specific batch.

    The Paul-Ehrlich-Institut (PEI) reports suspected side effects with Comirnaty, but it does not confirm these as side effects, nor does it link them to specific batches.

    Most side effects of Comirnaty are mild. These are not batch specific and are clearly listed in the product information with the respective frequency.

    A conditional marketing authorisation was granted by the Commission to Comirnaty in December 2020, based on EMA’s rigorous scientific evaluation, weighing up the benefits and risks.

    The conditional marketing authorisation was converted into a standard marketing authorisation on 10 October 2022. After authorisation in 2020, EMA has been continuously monitoring suspected side effects and evaluating any new information that emerges[2]. This evaluation is conducted by EMA’s expert committees, and action is taken, if necessary.

    Comirnaty continues to fulfil the necessary requirements for authorisation in the EU.

    • [1] Vaccine safety (Comirnaty): https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/coronavirus-disease-covid-19/covid-19-medicines/covid-19-vaccines-key-facts
    • [2] https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty#authorisation-details
    Last updated: 20 February 2025

    MIL OSI Europe News

  • MIL-OSI Asia-Pac: India is no longer just a follower; it is now leading the way in multiple fields: Dr. Jitendra Singh

    Source: Government of India (2)

    Posted On: 19 FEB 2025 3:04PM by PIB Delhi

    • India’s Space Sector Soars: From Chandrayaan-3 to Bharatiya Antariksh Station, Nation Emerges as a Global Leader in Space Exploration
    • India Leads Global Healthcare Innovation with DNA-Based COVID-19 Vaccine and First Herpesvirus Vaccine for Cervical Cancer
    • India’s Bioeconomy Booms: From $10 Billion to $140 Billion, Poised to Reach $250 Billion with Thriving Biotech Startups
    • India Pioneers Space Biology: Advancing Research in Space Medicine and Sustainable Life Beyond Earth
    • India’s Nuclear Energy Vision: 100 GW by 2047 to Drive Sustainability and Global Climate Leadership
    • India Rises as a Global Research Powerhouse, Poised to Lead the World in Scientific Publications by 2030
    • India’s Space Economy Poised for 10X Growth, Strengthening Global Leadership in Science and Bio-Manufacturing

    Union Minister of State (Independent Charge) for Science and Technology; Earth Sciences and Minister of State for PMO, Department of Atomic Energy, Department of Space, Personnel, Public Grievances and Pensions, Dr. Jitendra Singh has asserted that India is no longer just a follower but is now setting global benchmarks, offering leadership and pioneering innovations across sectors. He highlighted the remarkable advancements India has made in recent years, in the fields of space, biotechnology, and nuclear energy etc positioning itself as a key player on the world stage.

    Dr. Jitendra Singh pointed out that India’s space sector has witnessed an unprecedented transformation, with a surge in ambitious missions and international collaborations. The Space Docking Experiment (SpaDeX) is a testament to India’s technological progress, paving the way for future space missions, including Gaganyaan, Chandrayaan-4, and the Bharatiya Antariksh Station, India’s upcoming international space station.

    India has also emerged as a preferred destination for satellite launches, earning global credibility. The nation has successfully launched 433 foreign satellites, of which 396 were deployed in the last decade alone, generating $157 million and €260 million in revenue from 2014-2023. The historic success of Chandrayaan-3, which made India the first country to land near the Moon’s south pole, has positioned ISRO at the forefront of lunar exploration. The world’s leading space agencies, including NASA, are now awaiting India’s findings from the Moon’s southern pole, a milestone that underscores the nation’s rising dominance in space research.

    The Minister also highlighted India’s pioneering role in biotechnology and bioeconomy. India became the first country to develop a DNA-based COVID-19 vaccine, demonstrating its leadership in vaccine research and development. Furthermore, India has introduced the first herpesvirus vaccine for cervical cancer, reinforcing its position as a leader in preventive healthcare.

    India’s bioeconomy has surged from $10 billion in 2014 to nearly $140 billion today, with projections to reach $250 billion in the coming years. The number of biotech startups has skyrocketed from just 50 in 2014 to nearly 9,000 today, making India a global hub for biotech innovation. In bio-manufacturing, India now ranks third in the Asia-Pacific region and 12th globally, with its influence expanding rapidly.

    India has also taken a bold step into space biology, laying the foundation for human survival beyond Earth. ISRO and the Department of Biotechnology have signed an MoU to advance space biotechnology research, focusing on growing plants in space to sustain long-term space missions. The study of space medicine and human physiology in extraterrestrial environments is becoming a critical area of research, and India is now setting global standards instead of just following them.

    India’s nuclear energy program, once met with scepticism, is now recognized for its peaceful and sustainable ambitions. The country has set an ambitious target of 100 gigawatts of nuclear energy by 2047, aiming to reduce carbon emissions by 50%, a commitment that is influencing global climate strategies. The world has now acknowledged India’s nuclear policy, which was envisioned by Homi Bhabha for peaceful purposes, as a model for responsible energy development.

    India’s scientific output is gaining global recognition, with the country now ranked fourth worldwide in scientific publications. Projections suggest that by 2030, India could surpass the United States to become the world’s top-ranked country in scientific research.

    India’s space economy is set to grow 5 to 10 times in the next decade, further solidifying its leadership. The nation’s rapid economic ascent is evident in its global rankings, including its 12th position in bio-manufacturing and fourth place in scientific research publications.

    Dr. Jitendra Singh concluded by emphasizing that India’s rise is no longer just about catching up but about setting the agenda for the world. “The clock has turned 360 degrees. Earlier, we learned from others; now, the world is looking up to us. The traffic is both ways,” he remarked.

    *****

    NKR/PSM

    (Release ID: 2104674) Visitor Counter : 20

    MIL OSI Asia Pacific News

  • MIL-OSI United Kingdom: expert reaction to study looking at life expectancy changes in 20 European countries from 1990-2021

    Source: United Kingdom – Executive Government & Departments

    A study published in The Lancet Public Health looks at life expectancy changes across 20 European countries from 1990-2020. 

    Prof Jennifer Dowd, Professor of Demography and Population Health, University of Oxford, said:

    Does the press release accurately reflect the science?

    “While accurate overall, the press release at times oversimplifies and overstates the conclusions of the paper, including the press release title: “We are no longer living longer.”  The paper looks at mortality trends from 1990-2021 and finds slowing improvements in life expectancy in the decade prior to COVID–but improvements still mean we are living longer.  Life expectancy declined due to COVID-19 in 2020 and 2021, but this is likely a temporary shock and doesn’t mean we will die sooner than our parents and grandparents, as implied. The press release also states that food, physical activity, and obesity are largely to blame for these trends, but this overstates what we can confidently say about these causes.”

     

    Is this good quality research?  Are the conclusions backed up by solid data?

    “This is good quality research, especially in the standard estimation of life expectancy trends and the causes of death contributing to these trends. The part of the analysis that tries to attribute slower mortality improvements to specific risk factors such as cholesterol, hypertension, and “dietary risks” is on shakier ground. The estimates used for this part of the analysis were based on different data and analysis that are not discussed in detail here. The estimation of how risk factors such as diet causally impact mortality is methodologically very challenging, and there is a lot of uncertainty about any single estimate. In addition, the population-representative data on the prevalence and trends of these risk factors across all the countries is not readily available. Putting these two sources of uncertainty together means it is very difficult to attribute country-level life expectancy trends to specific risk factors with high confidence. The “under the hood” part of how these estimates are produced is largely glossed over in the paper, but they are presented as established facts.”

    How does this work fit with the existing evidence?

    “The analysis of trends in life expectancy is consistent with previous work that has shown similar trends and slowdowns in improvements in the decade prior to COVID. For example, see a recent review “Progress Stalled? The Uncertain Future of Mortality in High-Income Countries”

    Have the authors accounted for confounders?  Are there important limitations to be aware of?

    “The portion of the paper attributing life expectancy changes to specific risk factors like diet and physical activity is based on other analyses that are highly vulnerable to bias due to confounding. The conclusions for this portion of the analysis should be tempered.”

     

    What are the implications in the real world?  Is there any overspeculation? 

    “We are seeing slowdowns in life expectancy improvements after decades of often rapid gains. But even slow improvements mean we are living longer on average. Slowing improvements may be a warning sign of things to come, so we need to continue tracking these trends. This paper makes strong statements about the specific risk factors responsible for slowing life expectancy improvements, including obesity, high cholesterol, and “occupational risks.” While these risk factors are no doubt important for health, we can’t say with certainty how each one contributes to these trends.”

     

    How confident can we be as to the causes of the decline in life expectancy in England?

    “The reported decline in life expectancy in England was only during COVID. Prior to that there were slower improvements in life expectancy compared to the previous period and compared to other countries. There is not broad agreement on the cause of these slowdowns, as it is difficult to directly test mechanisms such as austerity cuts. We have good evidence that the slower improvements were largely attributable to slowing improvements in cardiovascular disease, as well as some increases in external cause mortality such as drug deaths at younger ages and midlife. For more thorough examinations, please see paper here and here.”

     

    Could these trends be potentially linked to current state of NHS/ waiting lists? Also could the use of weight-loss drugs potentially help reverse this trend if they tackle rising obesity rates?

    “Challenges with the NHS are one potential contributor to mortality trends in England, but the size of their contribution is not well established. These trends likely reflect much longer-term trends in risk factors such as obesity that accumulate over time. Since the obesity epidemic is now many decades old, more people are entering midlife and older age having been obese for a long time, which could be contributing to these trends. There is cautious optimism that the new GLP-1 class of diabetes and weight-loss drugs could be a game-changer for treating obesity have some long-term benefits for life expectancy, though more evidence is needed to confirm this.”

    Dr Yize Wan, NIHR Clinical Lecturer in Intensive Care Medicine & Anaesthesia, William Harvey Research Institute (WHRI), Queen Mary University London (QMUL), said:

    “The reasons for these findings are complex and likely to be a combination of both individual risk factors from health behaviours and the need to improve access and delivery of healthcare systems. This study has highlighted the importance of addressing modifiable risk factors and preventing and not just treating long-term disease. It would be important to see if these trends are seen across the whole population or whether people from more socioeconomically deprived or different ethnic backgrounds are disproportionally affected. Particularly as we know that socioeconomically and ethnically disadvantaged population groups are more likely to be exposed to common risk factors such as poor diet and low physical activity as well as have more limited access to healthcare.”

     

    Prof Tom Sanders, Professor emeritus of Nutrition and Dietetics, King’s College London (KCL), said:

    “This is a useful analysis of changes in life expectancy across Europe since 2011 compared with the period 1990-2011.  Prior to this life expectancy had increased by about 11 years compared with 1960s for a variety of reasons particularly better control of high blood pressure, blood pressure and immunisation against flu as well as lifestyle changes (smoking cessation and better diet) including increased prosperity. This study shows overall across the 20 countries there was an improvement in life expectancy increased from 1990 up to 2011 by on average 0.23 years but this rate of improvement slowed to 0.15 years between 2011 and 2019. The UK, France and Germany showed bigger declines in life-expectancy compared to the Nordic countries.

    “It is important to recognise that the demographics of the European population have changed markedly in some countries such as the UK, France and Germany because of increased migration compared to Nordic countries. In the UK, the population growth had been due to migration often from countries where life expectancy is much lower.

    “The authors attribute the small decline in life-expectancy to increasing prevalence of obesity particularly in younger and middle-aged adults. While, obesity is likely to contribute to decreased life expectancy in future generations, the prevalence was not particularly high in the older generation, who accounted for most of the deaths in the period 2011-2019.”

    Changing life expectancy in European countries 1990–2021: a subanalysis of causes and risk factors from the Global Burden of Disease Study 2021’ by Nicholas Steel et al. was published in The Lancet Public Health at 23:30 UK time Tuesday 18th February 2025. 

    DOI: 10.1016/S2468-2667(25)00009-X

    Declared interests

    Dr Yize Wan: I have no declarations of interest.

    Prof Jennifer Dowd: No conflicts.

    For all other experts, no reply to our request for DOIs was received.

    MIL OSI United Kingdom

  • MIL-OSI USA: With Flu and Norovirus Levels High, Good Health Habits Recommended

    Source: US State of Rhode Island

    With rates of seasonal viruses, such as flu and norovirus, still elevated throughout Rhode Island, the Rhode Island Department of Health (RIDOH) is urging people to practice good health habits to help keep everyone healthy and safe.

    So far, more than 900 people in Rhode Island have been hospitalized with influenza this flu season, the most since the 2019-2020 flu season. (Individual cases of flu are not reportable to RIDOH.) Since December 1, 2024, Rhode Island has had 74 confirmed or suspected norovirus outbreaks. Rhode Island’s norovirus outbreaks have largely been associated with locations such as schools and congregate living settings.

    Flu and other respiratory viruses (such as COVID-19 and RSV, or respiratory syncytial virus) spread when an infected person coughs or sneezes, by direct contact with someone who is sick, or by touching a contaminated surface.

    Norovirus, often called the “stomach flu” or “stomach bug,” causes vomiting and diarrhea and spreads quickly. It can make people very sick for 1 to 2 days. Norovirus is found in the stool (poop) and vomit of an infected person. People can become infected with norovirus by eating food or drinking liquids that are contaminated with norovirus; by touching surfaces or objects that are contaminated with norovirus and then touching their mouth; or if an infected person prepares food. People can even get infected with norovirus after a sick person has vomited in a public space because tiny drops of vomit from a person with norovirus can spray through the air, landing on surfaces or entering another person’s mouth.

    “The flu is a very serious virus that can send someone to the hospital, and norovirus can be dangerous for some people too,” said Director of Health Jerry Larkin, MD. “Both viruses spread easily. However, by taking a few simple preventive steps, you can help keep yourself and those around you safe. These steps are especially important for people who are at higher risk due to underlying medical conditions or pregnancy, as well as younger children and older adults.”

    How to prevent flu and other respiratory viruses (such as COVID-19 and RSV):

    – Everyone 6 months or older should get a flu shot and an updated COVID-19 vaccine. It is not too late in the year to get vaccinated against either virus. Vaccination is particularly important for older adults and people with underlying health issues such as weakened immune systems, diabetes, obesity, asthma, cancer, and heart or lung disease. Many people are also eligible for RSV immunizations. Talk to your healthcare professional about RSV immunization.

    – Stay home and away from others until your symptoms are getting better for 24 hours and you are fever-free without fever-reducing medications for 24 hours. Children who are sick should not go to school or childcare.

    – Wash your hands often throughout the day. Use warm water and soap. If soap and water are not available, use alcohol-based hand gel.

    – Cover your mouth and nose with a tissue when you cough or sneeze. If you don’t have a tissue, cough or sneeze into your elbow, not your hands. Always wash your hands as soon as you can after you cough or sneeze.?

    How to prevent norovirus:

    – Wash your hands carefully with soap and water, especially after using the toilet, changing diapers, and before eating or preparing food. Hand sanitizer alone does not work well against norovirus.

    – Stay home if you are sick and keep children home from school and childcare if they are sick. Stay home when sick for 2 days (48 hours) after symptoms stop.

    – After an episode of illness, such as vomiting or diarrhea, immediately clean and disinfect contaminated surfaces by using a bleach-based household cleaner as directed on the product label or a solution made by adding 5�25 tablespoons of household bleach to 1 gallon of water.

    – Do not prepare food while infected. People who are infected with norovirus should not prepare food for others while they have symptoms and for 3 days after they recover from their illness.

    While levels of flu and norovirus are high, Rhode Island’s COVID-19 rate has been decreasing since early January. Rhode Island’s COVID-19 rate is considerably lower than it was at this time in 2024.

    MIL OSI USA News

  • MIL-OSI Europe: Written question – Why did the Pfizer/BionTech agreement waive serialisation? – P-000624/2025

    Source: European Parliament

    Priority question for written answer  P-000624/2025
    to the Commission
    Rule 144
    Christine Anderson (ESN)

    The unredacted Advance Purchase Agreement (APA) for the development, production, priority-purchasing options and supply of a successful COVID-19 vaccine for EU Member States has now been published online[1].

    I quote from Annex I (Vaccine Order Form), Article I(4), page 49: ‘Further, to the extent applicable, the Participating Member State acknowledges that the Vaccine shall not be serialized’.

    The term ‘serialise’ typically refers to the process of uniquely identifying each vaccine dose or package with a distinct identifier, such as a serial number, barcode or QR code.

    By waiving the serialisation of the vaccine, the APA, as negotiated by the Commission, has made it impossible to uniquely identify each dose and track it from production to delivery and eventual administration.

    • 1.What is the reason for this, other than to create obstacles to being able to hold Pfizer liable in the event of sub-standard vaccines?
    • 2.How is this compliant with the Falsified Medicines Directive[2], which mandates the serialisation of medicinal products?
    • 3.Did the Commission not see how not serialising the vaccine would create difficulties for tracking, tracing and monitoring vaccine distribution and administration, managing inventory levels, gathering and sharing information, ensuring accountability, and recalling the product, especially in the light of the fact that this was a largely untested product that was destined to be administered to hundreds of millions of EU citizens?

    Submitted: 11.2.2025

    • [1] https://archive.org/details/contract_03.
    • [2] Directive 2011/62/EU of the European Parliament and of the Council of 8 June 2011 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use, as regards the prevention of the entry into the legal supply chain of falsified medicinal products, OJ L 174, 1.7.2011, p. 74, ELI: http://data.europa.eu/eli/dir/2011/62/oj.
    Last updated: 17 February 2025

    MIL OSI Europe News

  • MIL-OSI Asia-Pac: Animal Husbandry & Dairying Department and World Organisation for Animal Health Set Roadmap for Public Private Partnerships in the Livestock Sector

    Source: Government of India (2)

    Animal Husbandry & Dairying Department and World Organisation for Animal Health Set Roadmap for Public Private Partnerships in the Livestock Sector

    Workshop Focuses on District Level Veterinary Laboratories, FMD Free Zones, Robust Vaccine Value Chain; To Boost Animal Health in India

    Need to Develop a Structured PPP Policy within One Year to Strengthen Veterinary Services in India: Secretary DAHD

    Posted On: 15 FEB 2025 1:14PM by PIB Delhi

    The Department of Animal Husbandry & Dairying (DAHD), under the Ministry of Fisheries, Animal Husbandry and Dairying in collaboration with the World Organisation for Animal Health (WOAH), successfully organized the WOAH PVS-PPP (Performance of Veterinary Services-Public Private Partnership) Targeted Support Workshop from 11th to 13th February 2025 in New Delhi. The workshop aimed to strengthen the veterinary services through public-private partnerships (PPP) in areas such as vaccine platforms, veterinary workforce development, institutional infrastructure, and the creation of Foot-and-Mouth Disease (FMD)-Free Zones.

    The discussions centered on bridging the critical gaps in veterinary services in India through structured PPP engagement, with emphasis on:

    • Expanding veterinary infrastructure, including the establishment of NABL-accredited veterinary laboratories at the district level.
    • Strengthening disease control programs through enhanced surveillance and FMD-Free Zone development.
    • Building veterinary workforce capacity through structured training and knowledge-sharing platforms.
    • Strengthening self-reliance in veterinary vaccine production by developing a robust vaccine value chain.
    • Defining a comprehensive PPP policy framework to integrate private sector expertise in veterinary research, diagnostics, and extension services.

    Ms. Alka Upadhyaya, Secretary, DAHD, highlighted the critical role of veterinary services in supporting the livestock sector, which contributes over 30% to India’s Agricultural Gross Value Added (GVA). She underscored the need for establishing veterinary laboratories with NABL accreditation and emphasized that private sector collaboration is essential for disease surveillance, workforce capacity, and vaccine production. “This workshop has created a platform for structured PPP engagement in veterinary services. The discussions will contribute to a roadmap that enhances national disease control programs, expands veterinary infrastructure, and ensures a sustainable ecosystem for animal health security,” she said. Ms. Upadhyaya further emphasized the need for developing a structured PPP policy within a year to ensure long-term investment and private sector participation in veterinary services.

    Dr. Hirofumi Kugita, World Organization for Animal Health, Regional Representative for Asia and the Pacific, acknowledged India’s leadership in veterinary services and its potential to contribute to global best practices through knowledge-sharing and laboratory collaborations.

    Dr. Abhijit Mitra, Animal Husbandry Commissioner and the chief veterinary officer of the country, noted that scaling up veterinary services requires a structured institutional framework where the public and private sectors work together. He said, “This workshop has set the groundwork for defining such a framework, and the next steps will focus on execution and capacity building”.

    The workshop brought together over 100 participants from State Animal Husbandry Departments, Veterinary Councils, Disease Diagnostic Laboratories, ICAR research institutes, Agent for Health and Extension of Livestock Production (A-HELP), the Agriculture Skill Council of India, the Central Drugs Standard Control Organization, private sector stakeholders, Indian Federation of Animal Health Companies (INFAH), vaccine manufacturers, Food and Agriculture Organization and the World Bank. Seven WOAH experts facilitated discussions, defining PPP strategies for resource mobilization, risk management, and stakeholder integration during the workshop. The workshop concluded with the presentation of a PPP Roadmap for the Veterinary Sector, outlining actionable strategies to enhance veterinary services, disease surveillance, and livestock productivity. The outcomes will contribute to policy development, investment mobilization, and structured PPP implementation, ensuring long-term benefits for India’s animal husbandry sector.

    ****

    Aditi Agrawal

    (Release ID: 2103484) Visitor Counter : 31

    MIL OSI Asia Pacific News

  • MIL-OSI USA: Keeping Education Accessible and Ending Covid-19 Vaccine Mandates in Schools

    US Senate News:

    Source: The White House
    By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ordered:
         Section 1.  Purpose and Policy.  Some school districts and universities continue to coerce children and young adults into taking the COVID-19 vaccine by conditioning their education on it, and others may re-implement such mandates.  Parents and young adults should be empowered with accurate data regarding the remote risks of serious illness associated with COVID-19 for children and young adults, as well as how those risks can be mitigated through various measures, and left free to make their own decisions accordingly.  Given the incredibly low risk of serious COVID-19 illness for children and young adults, threatening to shut them out of an education is an intolerable infringement on personal freedom.  Such mandates usurp parental authority and burden students of many faiths.    It is the policy of my Administration that discretionary Federal funds should not be used to directly or indirectly support or subsidize an educational service agency, State educational agency, local educational agency, elementary school, secondary school, or institution of higher education that requires students to have received a COVID-19 vaccination to attend any in-person education program.
         Sec. 2.  Definitions.  For the purposes of this order:  (a)  The term “educational service agency” has the meaning given in 20 U.S.C. 1401(5).(b)  The term “elementary school” has the meaning given in 34 C.F.R. 77.1(c). (c)  The term “institution of higher education” has the meaning given in 20 U.S.C. 1001(a). (d)  The term “local educational agency” has the meaning given in 34 C.F.R. 77.1(c).(e)  The term “secondary school” has the meaning given in 34 C.F.R. 77.1(c). (f)  The term “State educational agency” has the meaning given in 34 C.F.R. 77.1(c).
         Sec. 3.  Ending COVID-19 Vaccine Mandate Coercion.  (a)  The Secretary of Education shall as soon as practicable issue guidelines to elementary schools, local educational agencies, State educational agencies, secondary schools, and institutions of higher education regarding those entities’ legal obligations with respect to parental authority, religious freedom, disability accommodations, and equal protection under law, as relevant to coercive COVID-19 school mandates.(b)  Within 90 days of the date of this order, the Secretary of Education, in consultation with the Secretary of Health and Human Services, shall provide to the President, through the Assistant to the President for Domestic Policy, a plan to end coercive COVID-19 school mandates, consistent with applicable law, and including, as appropriate, any proposed legislation.  Such plan shall also include:(i)   a list of discretionary Federal grants and contracts provided to elementary schools, local educational agencies, State educational agencies, secondary schools, and institutions of higher education that are non-compliant with the guidelines issued pursuant to subsection (a) of this section; and(ii)  each executive department or agency’s process for, to the maximum extent consistent with applicable law, preventing Federal funds from being provided to, and rescinding Federal funds from, elementary schools, local educational agencies, State educational agencies, secondary schools, and institutions of higher education that are non-compliant with the guidelines issued pursuant to subsection (a) of this section.
         Sec. 4.  General Provisions.  (a)  Nothing in this order shall be construed to impair or otherwise affect:(i)   the authority granted by law to an executive department or agency, or the head thereof; or(ii)  the functions of the Director of the Office of Management and Budget relating to budgetary, administrative, or legislative proposals.(b)  This order shall be implemented consistent with applicable law and subject to the availability of appropriations.(c)  This order is not intended to, and does not, create any right or benefit, substantive or procedural, enforceable at law or in equity by any party against the United States, its departments, agencies, or entities, its officers, employees, or agents, or any other person.

    MIL OSI USA News

  • MIL-OSI USA: Senator Murray: Trump Move Undermining Vaccines Is Straight-Out Pro-Sickness

    US Senate News:

    Source: United States Senator for Washington State Patty Murray

    Washington, D.C. – Today, U.S. Senator Patty Murray (D-WA), senior member and former chair of the Senate Health, Education, Labor, and Pensions Committee, and a former local school board member, released the following statement in response to President Trump signing an Executive Order barring federal funding from schools and universities with COVID-19 vaccination requirements.

    “This continues to show that President Trump and Secretary Kennedy are just straight-out pro-sickness. It is entirely unconscionable, and unethical. Vaccine requirements are not new, nor are the exceptions that have long existed. Schools and states decide their vaccine policies, often after consulting public health officials, and should never be asked to sacrifice student safety for federal funding. This executive order undermines confidence in the COVID vaccine, and this fact-free, anti-vaccine policy, along with Republicans’ full endorsement of a vaccine skeptic as our nation’s top health official, will dangerously turbocharge distrust in lifesaving vaccines across the board—despite all the evidence showing they are safe. Let’s also be clear: an administration that talks a big game about empowering local communities to make decisions for themselves is now creating a sweeping and dangerous new mandate—telling every school in America to pick between funding to keep teachers on the job and keeping students safe.”

    MIL OSI USA News

  • MIL-OSI United Nations: Experts of the Committee on Economic, Social and Cultural Rights Commend the United Kingdom on Steps Taken to Provide a Real Living Wage, Ask Questions on Reported Discriminatory Legislation for Asylum Seekers and High Levels of Child Poverty

    Source: United Nations – Geneva

    The Committee on Economic, Social and Cultural Rights today concluded its review of the seventh periodic report of the United Kingdom of Great Britain and Northern Ireland, with Committee Experts commending the steps taken to provide a real living wage, while asking questions on reported discriminatory legislation for asylum seekers and high levels of child poverty in the State party. 

    Joo-Young Lee, Committee Expert and Taskforce Member, said in its reply to the list of issues, the State party stated that the level of the minimum living wage for this year would be set at a level not below two-thirds of the median earnings in the United Kingdom.  For the first time, the cost of living would also be taken into account in this process, with the aim of providing a real living wage, which was commendable. 

    Seree Nonthasoot, Committee Expert and Taskforce Leader, said it had been reported that the discriminatory effects of such recent legislation as the Nationality and Borders Act 2022, the Illegal Migration Act 2023, and the Safety of Rwanda (Asylum and Immigration) Act 2024 had hindered access by migrants in an irregular situation and asylum seekers to social protection benefits.  Could the State party clarify if these hindering measures were in place and if social benefits would be ensured to this marginalised group?

    Julieta Rossi, Committee Expert and Taskforce Member, said the United Kingdom was one of the richest economies in the world, yet extremely high figures of poverty persisted. According to information, during the period 2022/2023, 21 per cent of the population lived in relative poverty, with alarming rates of 30 per cent in childhood, or 4.3 million children.  Was the State developing a strategy to achieve a drastic and short-term reduction of poverty, which prioritised child poverty and poverty of disadvantaged groups? 

    The delegation said last month, a new border security, asylum and immigration bill was introduced to parliament, which included the repeal of the Safety of Rwanda Act and amended the Illegal Migration Act, including the duty to remove individuals who had arrived in the United Kingdom immediately.  The Nationality and Borders Act remained in place, but all asylum claims were individually considered in line with international obligations. 

    Concerning child poverty, the delegation said the United Kingdom Government was developing a child poverty strategy to be launched in spring, as part of a 10-year strategy to address the issue.  The strategy would look at increasing incomes, reducing essential costs, and better local support.  The incoming Government had committed to ending dependence on emergency food parcels. In the financial year 2025/2026, funding of 742 million pounds would be devolved to local governments to help address this issue.

    Robert Linham, Deputy Director, Rights Policy, Ministry of Justice of the United Kingdom and head of the delegation, introducing the report, said the United Kingdom had a system of asymmetric devolution.  The position of the United Kingdom Government remained that incorporation was not necessary for the Covenant’s full implementation, which had been secured through a combination of policies and legislation.  But the Scottish Government had embarked on a programme to incorporate international treaties into Scots law.  Regarding the right to work, increasing the number of people in work was central to the United Kingdom Government’s mission to grow the economy.  Proposals, backed by 240 million pounds of investment, had been announced to reform employment support and create an inclusive labour market. 

    In concluding remarks, Mr. Nonthasoot extended appreciation to the United Kingdom delegation for its superb time and sequence management, which allowed the Committee to raise all relevant questions.  The Committee implored the United Kingdom to ensure that all Crown Dependencies and Overseas Territories under its control provided the highest standard of human rights to everyone. 

    In his concluding remarks, Mr. Linham said the dialogue had been rich and detailed, covering a variety of issues.  It was hoped that the Committee could see the efforts being undertaken in the whole of the United Kingdom to improve economic, social and cultural rights. 

    The delegation of the United Kingdom was comprised of representatives from the Ministry of Justice; the Ministry of Housing Communities and Local Government; the United Nations Human Rights and IMA Policy Team; the Department for Business and Trade; the Department for Digital, Culture, Media and Sport; the Department for Education; the Department for Work Pensions; the Department for Environment, Food and Rural Affairs; the Department for Energy and Net Zero; the Department of Health and Social Care; the Foreign, Commonwealth and Development Office; the HM Treasury; the Home Office; the Scottish Government; the Welsh Government; the Northern Ireland Executive Office; the Attorney General’s Chambers for the Isle of Man; the Government of Jersey; and the Permanent Mission of the United Kingdom to the United Nations Office at Geneva.

    The Committee’s seventy-seventh session is being held until 28 February 2025.  All documents relating to the Committee’s work, including reports submitted by States parties, can be found on the session’s webpage.  Webcasts of the meetings of the session can be found here, and meetings summaries can be found here.

    The Committee will next meet in public at 3 p.m. on Monday, 17 February to begin its consideration of the fifth periodic report of Rwanda (E/C.12/RWA/5).

    Report

    The Committee has before it the seventh periodic report of the United Kingdom of Great Britain and Northern Ireland (E/C.12/GBR/7).

    Presentation of Report

    ROBERT LINHAM, Deputy Director, Rights Policy, Ministry of Justice of the United Kingdom and head of the delegation, said the United Kingdom had a system of asymmetric devolution by which specified areas of responsibility were devolved to some or all of Northern Ireland, Scotland and Wales.  For example, health and education were devolved to all three nations; social security was fully devolved to Northern Ireland but only in part to Scotland; and immigration was largely reserved to the United Kingdom Government.  The delegation also represented the three Crown Dependencies: the Bailiwick of Jersey, the Bailiwick of Guernsey, and the Isle of Man, as well as the 14 British Overseas Territories, home to 250,000 people. 

    One example of devolution in practice related to the incorporation of the Covenant into national law.  The position of the United Kingdom Government remained that incorporation was not necessary for the Covenant’s full implementation, which had been secured through a combination of policies and legislation; and further what it would take to incorporate the Covenant would not be justified by the benefits.  But the Scottish Government had embarked on a programme to incorporate international treaties into Scots law. Its incorporation of the Convention on the Rights of the Child, with two Optional Protocols, came into force last July; and the Scottish Government had committed, subject to the outcome of the next election, to introduce a human rights bill in the next session of Parliament that would give domestic legal effect in Scots law to the present Covenant and some other United Nations treaties.

    Since the restoration of the Northern Ireland Executive and political institutions in February last year, new initiatives had been launched, including an additional 25 million pounds to support early learning and childcare, the provision of free period products to anyone who needed them, and a strategy to end violence against women and girls.  The United Kingdom general election in June 2024 resulted in a change of government to the Labour Party.  In some areas, the approach had already changed quite radically, while other policies remained under review. 

    Regarding the right to work, increasing the number of people in work was central to the United Kingdom Government’s mission to grow the economy.  Proposals, backed by 240 million pounds of investment, had been announced to reform employment support and create an inclusive labour market. Last October, the Government also introduced an employment rights bill into the United Kingdom’s Parliament to increase workers’ rights to better working conditions and more secure work, and to improve industrial relations.  It also included protections from sexual harassment; gender and menopause action plans; and enhanced rights for pregnant workers.

    In the same vein, Guernsey enacted legislation that formally made discrimination on the grounds of race, disability, carer status, religion or belief, and sexual orientation unlawful, covering the fields of employment, the provision of goods and services, accommodation, and membership of clubs and associations.

    Regarding the right to health, England introduced the “Core 20 Plus 5” approach to reduce healthcare inequalities, amongst the most deprived 20 per cent of the population. The Government’s goal was to halve the gap in healthy life expectancy between England’s richest and poorest regions, which in 2020 stood at 10.8 years.  The mental health bill, introduced into Parliament last November, sought to address inadequate care of autistic people and people with learning disabilities, and reduce their unnecessary detention.

    Using newly devolved powers as part of its goal to eradicate child poverty, the Scottish Government introduced five payments to eligible families.  Three Best Start Grants provided one-off payments at key stages in a child’s life.  Best Start Foods was a regular weekly payment to help buy milk and healthy food.  And the Scottish Child Payment helped with the costs of supporting a family.  Similarly, Wales offered free school meals to all children in State primary schools.

    In cultural rights, the United Kingdom last year ratified the 2003 United Nations Educational, Scientific and Cultural Organization Convention for the Safeguarding of Intangible Cultural Heritage.  In Wales, the Cymraeg 2050 Welsh Language Strategy saw almost 17,000 people studying with the National Centre for Learning Welsh in 2022/23, a 33 per cent increase over five years.  Regarding environmental commitments, finally, the Paris Agreement was extended to the Isle of Man, Jersey and Guernsey in 2022 and 2023. Mr. Linham said the United Kingdom was committed to upholding the rights set out in the Covenant. 

    Questions by Committee Experts

    SEREE NONTHASOOT, Committee Expert and Taskforce Leader, said the Committee, via the Secretariat, had received more than 72 submissions pertaining to the periodic report of the State party, probably the highest number thus far for any State party, which attested to the attention and interest that the international community and stakeholders gave to the State party and its report.  It was also important to note, following the submission of the report, that there was a general election in July 2024 and a new administration had since been appointed. 

    The Committee observed that the Covenant could not be applied directly by the State party’s domestic courts.  While there was alignment between the State party’s Human Rights Act 1998 and the European Convention on Human Rights, there was as yet no such transposition mechanism for the Covenant?  Was the Covenant applicable in Anguilla and Northern Ireland?  When would the nearly 50-year-old reservations to the Covenant be withdrawn?  Did the State party’s plan to ratify the Optional Protocol to the Covenant?

    The Committee recognised the State party’s record in introducing the first national action plan on business and human rights in the world in 2013, which was updated in 2016, and the Modern Slavery Act in 2015.  However, there was still an absence of a comprehensive legal framework for human rights due diligence, especially by United Kingdom companies in their transnational operations.  Could clarification on this be provided?  When would systematic and mandatory human rights due diligence be introduced? 

    Was the State party contemplating adopting a sectoral approach in the revision of the national action plan, where key sectoral performance indicators could be specified, for example in banking and finance, retail, construction, and health?  Did the State party intend to integrate effective remedial mechanisms, including legal aid to victims into the next national action plan and, more strategically, binding legislation? Would non-judicial recourse be provided for victims in extraterritorial cases?

    The Committee had scrutinised the 2024 report submitted to Parliament by the United Kingdom’s Climate Change Committee and found alarming findings.  The Committee concluded that only a third of the emissions reductions required to achieve the 2030 target were covered by credible plans, and low-carbon technologies must become the norm.  The Committee was also concerned that the devolved structure of the State party’s administrations had led to the fact that obligations arising from the Paris Agreement had not extended to all Crown Dependencies and Overseas Territories.  What was the concrete policy path to meet the action lines and targets, particularly home decarbonisation and adaptation?  How would the Paris Agreement have full coverage and effect in the territory of the State party?

    How was the State party addressing the tax system which had created negative impacts on vulnerable and marginalised groups, including the regressive nature of the value added tax on low-income households, and the welfare to work policies that posed a burden on people with disabilities?  In November 2024, the net public debt of the United Kingdom stood at 98.1 per cent.  How was this high public debt level impacting social budget programmes and what was the medium- and long-term direction on public debt management which would sustain basic public service investment and maintenance? 

    Could the State party provide policy trajectory on the concrete plan to tackle tax evasion and illicit financial flows, and in particular the reform of law and regulations in the British Virgin Islands, the Cayman Islands, Bermuda and other Overseas Territories that were indexed as tax havens?

    How did the new administration intend to address the regional disparity issue?  What were the cumulative impacts of the two austerity programmes implemented by the United Kingdom? 

    Had an assessment been carried out to implement the official development assistance restoration to 0.7% of the gross national income.  There were reports indicating that part of the development aid through British International Investment had caused impacts on key sectors responsible for delivering human rights, including health and education.  Could this be clarified?  The Committee was concerned by the lack of comprehensive anti-discrimination legislation; could the delegation provide more information around this? 

    While the State party had achieved good progress on gender equality, there were challenges in the fragmented and uneven legislative frameworks on women’s rights, particularly in Northern Ireland, Overseas Territories and Crown Dependencies. There were also news reports of incidents of sexual exploitation and violence against women and young girls by ‘grooming gangs’ in places like Oldham, north Manchester. Was this an isolated incident or a common occurrence and what had been done to address the issue?

    It had been reported that the discriminatory effects of such recent legislation as the Nationality and Borders Act 2022, the Illegal Migration Act 2023, and the Safety of Rwanda (Asylum and Immigration) Act 2024 had hindered access by migrants in an irregular situation and asylum seekers to social protection benefits.  Could the State Party clarify if these hindering measures were in place and if social benefits would be ensured to this marginalised group?

    Responses by the Delegation 

    The delegation said there was no obligation to incorporate the Covenant under domestic law. Successive Governments had explored ratifying the Optional Protocol and the view of previous Governments was that the protections were negligible.  The Covenant was applicable in England, Wales, Scotland, the three Crown Dependencies and the Overseas Territories.  Some of the reservations existing in the name of the United Kingdom related to territories which were no longer part of the United Kingdom, including the Solomon Islands and Tuvalu which were no longer British Overseas Territories, but sovereign States in their own right.   

    The Scottish Government had developed proposals to give domestic legal effect to the rights contained in the Covenant, by incorporating them into the Scottish legal framework.  The Government aimed to deliver a clear and workable law for the authorities that would implement it. 

    The Prime Minister had announced a commitment to reduce emissions by at least 81 per cent by 2035.  The target covered all sectors and categories and was aligned with the Paris Agreement. The United Kingdom was committed to extending its ratification of the Paris Agreement to all Overseas Territories and Crown Dependencies.  The Government had committed an additional 3.4 billion pounds to the “Warm Home Plan”, to support decarbonisation and cut bills for household heating. 

    The United Kingdom was committed to making the tax system fairer and more sustainable.  The Government had committed to not increasing tax on working people.  Recent tax changes had been targeted at the highest income households and working people had been largely protected from these tax increases.  Jersey was committed to introducing measures to reduce harmful tax measures.  Jersey’s 2019 economic substance law required companies to prove their genuine business activity, preventing those without real operations from artificially reporting profits. 

    A campaign had been launched against illicit finance.  At a recent joint ministerial council, the United Kingdom confirmed that Overseas Territories needed to implement fully public registers of beneficial ownership, which were key in targeting against corruption and tax evasion.  There were strong policies in place to monitor the impact of development aid programmes. 

    In recent years, there had been an increase in the representation of women in parliament, as well as in senior positions in the private sector, where women now represented 41 per cent.  The United Kingdom had mandatory gender pay gap reporting, which had shown a significant close in the size of the gender pay gap.  The current Government had introduced a bill which would introduce a new duty on employers to outline how they planned to close the gender pay gap. 

    There had been no agreement on a single equality bill in Northern Ireland, but numerous statutes had been enacted over the past few years.  Legislation now prohibited less favourable treatment in employment, education and public functions among others. 

    The safety of children was of paramount importance, but for too long grooming gangs had operated, victims had been ignored, and perpetrators had gone unpunished.  A 10-million-pound action plan to tackle grooming gangs and child sexual abuse had been announced, which would allow victims to have the chance to have their cases re-heard.  Survivors and victims would allow their closed cases to be reviewed by an independent panel, when they previously were not taken forward to prosecution by the Crown.  An audit would begin soon which would draw on the views of victims and survivors. 

    Last month, a new border security, asylum and immigration bill was introduced to parliament, which included the repeal of the Safety of Rwanda Act and amended the Illegal Migration Act, including the duty to remove individuals who had arrived in the United Kingdom immediately.  The Nationality and Borders Act remained in place, but all asylum claims were individually considered in line with international obligations. 

    Questions by Committee Experts

    SEREE NONTHASOOT, Committee Expert and Taskforce Leader, said reports had been received that the Northern Ireland human rights commission was at risk of losing its A status due to insufficient funding.  The Committee would like to raise this concern.  Why did the United Kingdom not adopt the same approach as the Scottish Government in incorporating the Covenant in domestic legislation so that all people could enjoy protection from the Covenant?  What was the State doing to reduce homelessness?  The Committee was very concerned that violent incidents against women would become systematic.  There should be a clear indication on how to prevent this type of violence. 

    JOO-YOUNG LEE, Committee Expert and Taskforce Member, asked what measures the Government would take to give full legal effect to the Covenant, and ensure victims of violations of economic, cultural and social rights had full access to legal remedies?  The Committee was pleased the Scottish Government had proposed the human rights bill, and hoped the provisions of the Covenant would be incorporated.  What was the plan to enact a bill of rights for northern Ireland?

    A Committee Expert asked how the State was planning a social green transformation? 

    Another Expert asked if there were any developments underway regarding the participation of the United Kingdom in the revised European Social Charter? 

    Responses by the Delegation 

    The delegation said all three of the human rights institutions had A status and adequate funding for their role.  At the most recent review of Northern Ireland, it was re-accredited with A status, and a baseline budget review had been launched for the Commission in 2024. 

    There was no obligation for direct justiciability for the rights of the Covenant under domestic law. The United Kingdom had no plans to ratify the revised European Social Charter. 

    It was intended that legislation in Scotland would increase accountability for the Covenant. 

    The debt to gross domestic product ratio was expected to fall in the final year of the five-year forecast. 

    The State would upgrade five million homes across the country through new technologies, including solar heat pumps and installation.  The transition to warmer, decarbonised homes would include support for the most vulnerable to combat fuel poverty.  Climate change would have a disproportionate impact on the most vulnerable of society, including those with pre-existing medical conditions.  The country’s climate change risk assessment took this into account and built into the development of the National Adaptation Programme.  It was essential that transition plans to net-zero were resilient in themselves.

    The Government was working on a strategy to end homelessness.  Last year, a funding increase was announced for homelessness services and initiatives were announced to allow renters to challenge rental increases. 

    Tackling violence against women and girls was a priority for the Government, and the State pledged to halve violence against women and girls within the next decade. 

    Questions by Committee Experts

    JOO-YOUNG LEE, Committee Expert and Taskforce Member, said that according to information that the Committee had received, although some employment gaps gradually narrowed over time, ethnic minorities, women, young people, and persons with disabilities continued to face higher levels of unemployment and were more likely to be in a low-paid jobs.  How had the State party analysed the underlying causes of employment and pay gaps, and what was the impact of these measures on ethnic minorities, women, young people and persons with disabilities in their access to decent work?

    Information received by the Committee indicated that the level of national minimum wage and national living wage was insufficient to ensure an adequate standard of living for workers, as it did not keep pace with the rising cost of living.  In its reply to the list of issues, the State party stated that the level of the minimum living wage for this year would be set at a level not below two-thirds of the median earnings in the United Kingdom. For the first time, the cost of living would also be taken into account in this process, with the aim of providing a real living wage, which was commendable.  Had the State party adopted a methodology for determining the level of the national minimum wage and the national living wage that was indexed to the cost of living. 

    What measures were being taken to address precarious work such as exploitative zero-hour contracts and to enhance security of employment?  What measures were taken to protect workers from labour exploitations and to impose appropriate sanctions on those responsible?  The Committee noted that the State party planned to establish a single body, a Fair Work Agency, to enhance the effectiveness of the protection of workers.  How would it be ensured that the body had necessary 

    powers and resources to effectively monitor working conditions and protect workers?  What measures were taken to ensure the right to strike?

    According to information received by the Committee, the level of social security benefits was not sufficient for a decent standard of living.  Information indicated that the social security system, including the Universal Credit, was not providing people with adequate social protection. What measures were being taken to ensure that the level of social security benefits was adequate and determined by an assessment of the real cost of an adequate standard of living?  Had the State party carried out an assessment of the impact on people of such measures as the benefit cap, the two-child policy, the so-called “bed-room tax” and the five-week wait, and if so, what measures were being taken to address these impacts?  What measures were being taken to ensure that any conditions for benefits were proportionate and did not result in stigmatisation and degradation of claimants?

    What measures had the State taken to ensure the availability, accessibility, and affordability of quality childcare, including childcare for disabled children?

    How was it ensured that quality social care was available, accessible, and affordable for adults who needed care and support, including older persons?

    Responses by the Delegation 

    The delegation said the creation of the national minimum wage had been one of the most successful economic interventions in the United Kingdom in the past 25 years.  The Government was determined to deliver a genuine living wage and had asked the Low Pay Commission to take account of the cost of living in recommending the appropriate rates for 2025 onwards.  The Low Pay Commission expected that three million low paid workers would receive a pay rise.  The Government had recently introduced an employment rights bill which would include a right to guaranteed hours.  There would be new rights to reasonable notice of shift cancellations, and the bills would close loopholes regarding scrupulous “fire to hire” practices. The Government aimed to protect workers and business from the minority of employers who broke the rules.   

    Migrant workers had the same employment rights and protections as other United Kingdom workers, including the minimum wage and protection against discrimination.  In 2023, it was ensured that all seasonal workers would receive at least 32 hours of work per week, and the minimum wage was also raised. 

    The employment rate for people of Bangladeshi and Pakistani origin had increased in recent years; historically this was low in the United Kingdom.  Levels of qualifications at schools were lower for some ethnic groups, which affected employment opportunities.  The State was planning to introduce mandatory pay reporting by ethnicity and disability. 

    A whitepaper would be published setting out the reforms expected by the Government on health and disability.  There were a range of ethnic minority support mechanisms in place. 

    The current rates of income-related benefits did not represent a minimum requirement, which could vary depending on people’s circumstances.  The current Government had committed to reviewing universal credit to tackle poverty.  The new child poverty strategy would focus on the benefit cap and the two-child limit. The Department for Work and Pensions published a range of independent evaluations in a wide range of social policy, including households below-average incomes. 

    The Government would provide more than eight billion pounds this year for education, representing a 30 per cent increase from the previous year.  Tax free childcare was a United-Kingdom wide offer to support parents to return to work, or work more when they needed to.  Families could receive up to 2,000 pounds per child per year, or 4,000 pounds if the child had a disability.   

    A fund could be used to increase funds paid to adult social care providers and reduce waiting times. The Care Act 2014 placed emphasis on local authorities to shape their care market, making sure they were meeting the needs of the local population. 

    In 2022, the Scottish Government published a refreshed Fair Work Vision, with a key goal of reducing the gender pay gap.  The median gender pay gap had decreased from 15.6 per cent in 2016, to 9.2 per cent in 2024. The disability employment had been reduced to around 37 per cent, which was its lowest level, with plans to halve the gap by 2028.  The Scottish Government was delivering 15 social security payments and was investing around 6.9 billion pounds in social security payments. 

    Questions by Committee Experts

    JOO-YOUNG LEE, Committee Expert and Taskforce Member, asked how the State would ensure the income-related benefits were adequate for those living in disadvantaged situations?  According to information, there may be a gap among the poorest of families for accessing childcare entitlements, particularly families that were not working. Could this be clarified? 

    A Committee Expert asked for examples where violations of the right of women workers compared to men had been judicially assessed?  What remedies were applied?

    Another Expert asked if there were plans for a participatory poverty assessment to be conducted every few years to identify those who were affected?   

    SEREE NONTHASOOT, Committee Expert and Taskforce Leader, asked if indexation based on inflation would be adopted, to more accurately reflect the living wage? 

    JULIETA ROSSI, Committee Expert and Taskforce Member, asked about the two-child cap on certain social security benefits, including universal credit.  This cap could have a huge impact on child poverty levels.  What was the rationale behind this?  What were the obstacles to immediately repealing the two-child limit?  The State had a high level of child policy, up to 30 per cent, so the Committee would appreciate more information being provided on this subject.

    Responses by the Delegation 

    The delegation said income-related benefits were rated annually in the United Kingdom, based on the level of the consumer-prices index.  As such, benefits for 2025 would be increased by 1.7 per cent.  The two-child cap was introduced as the United Kingdom faced a financial crisis a few years ago.  There was absolutely a relationship between the cap and the number of children in poverty.  The cap remained in place, but a taskforce was reviewing how the State would tackle the high levels of child poverty in the country, and would determine the best steps in this regard.  Removing the cap depended on the United Kingdom’s fiscal position. 

    The Low Pay Commission made annual recommendations on the appropriate rates of entities such as the minimum wage.  The Government’s impact assessment for 2025 found that women, younger and older workers, workers with a disability, and those from ethnic backgrounds, were more likely to be in minimum wage drops and more likely to benefit from the raising of the minimum wage in April 2025.  The Government had committed to reviewing the parental leave system to ensure it offered the best support to working families. 

    The Scottish Government had used other policies to determine the real living wage, including when issuing public sector grants and other funding.  The proposed human rights bill would aim to meet standards pertaining to the Covenant. 

    Working parent entitlements were established to support parents to return to work, which was why that entitlement was contingent on work.  Non-working families could access 15 hours of Government-funded early education. 

    The Education Minister in Northern Ireland was committed to bringing forward a strategy which would make childcare more affordable, among other initiatives.  A new childcare subsidy scheme had been implemented, and preschool education had been expanded, allowing more than 2,000 additional children to receive a fulltime place in 2025. 

    Questions by Committee Experts

    JULIETA ROSSI, Committee Expert and Taskforce Member, said the United Kingdom was one of the richest economies in the world, yet extremely high figures of poverty persisted.  According to information, during the period 2022/2023, 21 per cent of the population lived in relative poverty, with alarming rates of 30 per cent in childhood, or 4.3 million children.  Was the State developing a strategy to achieve a drastic and short-term reduction of poverty, which prioritised child poverty and poverty of disadvantaged groups? What measures had the State implemented in response to the recommendations of the review of child welfare care, as well as those issued by the Committee on the Rights of the Child in June 2023?

    According to statistics, food insecurity increased from 4.7 million to 7.2 million between 2021/22 and 2022/23, especially affecting low-income households.  What was the Government doing to address this alarming situation?  According to reports, there was a persistent housing crisis in the State party, including increasing rates of homelessness in the country, with most being women. Housing prices were high, as were mortgage rates, with rents rising higher than inflation in some parts of the country.  The lack of affordable housing for persons with disabilities was a factor which determined that they remained institutionalised, and there was inadequate initial accommodation for asylum seekers, among other issues.  What was the Government doing to address this crisis? 

    According to independent research commissioned by the Government in 2024, the National Health Service in England was in critical condition due to lack of funding, the impact of the COVID-19 pandemic, staff shortages and inefficiency in management. What were the details of the results of the investigation, and the drafting of a 10-year plan to address these issues? 

    Suicide rates remained high in the country, especially among men.  Persons with disabilities, gypsy, Roma and nomadic communities had high suicide rates compared to the general population.  Could information about the new mental health bill for England and Wales be provided?  What were the developments in other jurisdictions?

     

    Data from 2020 to 2022 showed the highest maternal mortality rates in England since 2003 to 2005, with a disproportionate impact on women in the most deprived areas. What were the results of the research commissioned by the Task Force on Maternal Disparities in 2022 and the policies in place to address this issue?  Access to sexual and reproductive care across the UK showed regional disparities; what measures had been adopted to unify this? 

    There had been a huge increase in drug-related deaths in the State party.  What plans and strategies were in place to prevent deaths, taking into account the disproportionate impact on certain communities? Were there plans to review the criminalisation of personal consumption and expand harm reduction services, including supervised drug consumption rooms?

    Responses by the Delegation 

    The delegation said the United Kingdom Government was developing a child poverty strategy to be launched in spring, as part of a 10-year strategy to address the issue. The strategy would look at increasing incomes, reducing essential costs, and offering better local support.  The incoming Government had committed to ending dependence on emergency food parcels.  In the financial year 2025/2026, funding of 742 million pounds would be devolved to local governments to help address this issue.

    Concerning support for families, the State’s response published in 2023 was to shift the focus away from crisis intervention and towards early help for families, ensuring children remained with their families as much as possible.  This was a multidisciplinary support offer which would work with the entire family at the earliest level possible.  When children could not remain with their families, they were supported to live with kinship families or foster families. 

    A social supermarket programme had been rolled out across all areas in Northern Ireland from 2022 to address food poverty.  Other support included debt and benefits advice, health food advice, and cooking on a budget.  A programme to tackle organized crime was established in 2016 and it had been extended until 2027.  Sexual and reproductive health services were provided across all five trust areas in Northern Ireland.  There were workforce challenges and the need for further investment. 

    The United Kingdom Government had committed to support first time home buyers.  The Government was seeking to deliver the biggest increase in affordable housing in a generation, with 110,000 to 130,000 social homes to be built over the next five years.  Since 2021, local authorities in England were required to ensure victims of domestic abuse and their children could access safe accommodation.  The Government would invest 160 million pounds in domestic safe accommodation in the next financial year. 

    Concerning Travellers, the Government aimed to ensure fair and equal treatment for them.  The revised policy for Traveller sites outlined that accommodation for Travellers should provide access for healthy lifestyles and health services. 

    The Scottish Government regarded poverty as a huge concern and had implemented the Child Poverty Act, which required poverty reduction plans to be published every four years.  Actions in the plans included raising incomes and lowering essential costs.  The Scottish Government had committed over three million pounds for remote rural and island health care.  The aim was to develop a model where services were provided as locally as possible, to ensure equitable outcomes. 

    Progress had been made in maternal care in the rural north of Scotland, via the plan which focused on restoring obstetric maternity care in the area.  The Scottish Government acknowledged that the number of drug and alcohol related deaths in Scotland remained too high.  The Government had launched a five-year mission to combat this, and the first “Safer Drug Consumption” facility in the United Kingdom had been opened in Glasgow last year. 

    One of the Government’s priorities was to clear the asylum backlog claims, and ensure people were housed in more effective and supervised accommodation.  Due to the exceptional number of unaccompanied children arriving in the United Kingdom from 2020, the Home Office had opened hotels to support these children, with a team residing within the hotels to support each child.  The teams included staff to provide medical and psychological support.  When the last hotel closed in 2024, all remaining children went directly into State care.  The United Kingdom had no plans to legalise or decriminalise drugs. 

    The mental health bill was introduced in November 2024 and would modernise the mental health act, including through addressing unnecessary detentions shaped by racial disparity.  The suicide strategy for England looked at what could be done for groups with higher suicide rates, including autistic people, Roma, refugees, asylum seekers and lesbian, gay, bisexual, transgender and intersex persons.   Anyone in England experiencing a mental health crisis could speak with a trained member of the National Health Service on the phone.  An additional 150 million pounds had been invested over the past two years to support mental health services.  Fifty million pounds would be invested into research into maternity inequalities to improve outcomes for all women.  England supported harm reduction activities, including needle and syringe testing.

    Welsh Ministers had a duty to submit child poverty objectives, and report on them every three years.  There was a targeted school meals programme for children. Over 3.4 million pounds had been made available as a capital grant fund for local Welsh authorities to fund residential or transit sites for Travellers.  The Welsh Government was currently finalising a new mental health strategy, with a focus on tackling inequalities. 

    Questions by Committee Experts

    A Committee Expert commended the delegation for being so well prepared and for their excellent time management.  What steps had the State party taken to ensure a more just and equitable financial architecture which prioritised human rights in lending policies?  What steps had the State taken for cancelling debt for countries in debt crisis?  What was the State party’s position on the use of compulsory license to promote access to health products in foreign countries? 

    SEREE NONTHASOOT, Committee Expert and Taskforce Leader, said the Scottish Government had provided a good example of safer drug consumption facilities.  Why did this not go hand in hand with decriminalisation?  What was the trajectory of decriminalisation?  Would the United Kingdom adopt a universal drug 

    policy which covered all its territories?

    JULIETA ROSSI, Committee Expert and Taskforce Member, said there was a pressing need to implement the child poverty strategy as soon as possible.  Could a more specific timeline for its implementation be provided?   The United Kingdom was one of the wealthiest countries in the world and had an obligation to earmark resources to reverse the situation of poverty in the country. How was the State addressing the issue of energy poverty? 

    JOO-YOUNG LEE, Committee Expert and Taskforce Member, said there was a concern that rent rises, in combination with a lack of social housing, were putting families at risk of homelessness.  What was being done to address this issue?

    Another Expert asked for measures adopted to address child obesity?  Were taxes on junk food being increased?

    An Expert asked about the emergency response in Northern Ireland to address the large number of deaths of homeless people?

    A Committee Expert asked what indicators were used to measure poverty?  Did the State use the multidimensional poverty index?

    Responses by the Delegation 

    The delegation said the child poverty strategy would be published in the spring, but acknowledged that people living in poverty needed help now.  In the meantime, steps had been taken to reduce the universal credit rate, which would benefit 1.2 million households.  Some of the challenges around food poverty related to incomes, rather than access to food, and this was being addressed in the food poverty strategy.  The United Kingdom used the universally recognised definition of poverty, which was measured by income. 

    There were no plans to change United Kingdom drug laws.  There was clear medical and scientific evidence which showed that controlled drugs were harmful.  There were no plans to extend United Kingdom drug legislation to the Overseas Territories.

    The United Kingdom had committed 1.6 billion pounds to Gavi, the Vaccine Alliance, which was committed to sustainable and equitable access of vaccines.  The National Health Service had doubled investment in gender dysphoria services and increased the number of clinics from seven to 12. 

    Obesity was concentrated within the most deprived areas.  The Government was addressing this by limiting school children’s access to fast food, preventing advertisements of the least healthy foods, and delivering schemes such as the healthy milk and the school fruit and vegetables scheme. 

    The United Kingdom was committed to working with partners to tackle unsustainable debt and coordinated with other official creditors to provide debt relief and promote debt sustainability for developing countries. 

    Scotland had released the Good Food Nation Plan in 2024, setting out the objectives the Government aimed to achieve on food related issues.  The long-term strategy for housing was published in 2021, addressing housing supply across the whole country, affordability and choice, and housing’s role in achieving net zero. 

    Northern Ireland was tackling homelessness through a strategy and had developed a strategic action plan for accommodation.  Funding for homelessness services would increase to nearly one billion pounds in England in the next financial year to prevent rough sleeping.

    A levy was applied to pre-packaged soft drink with an added five grams of sugar per 100 millilitres; drinks that contained less than five grams of sugar did not pay the levy, which was paid by packagers and importers.  The Government had committed an additional 3.5 million pounds over the next few years for the warm homes plan, with multiple targeted schemes in place to deliver energy assistance to low-income households.   

    The United Kingdom was supportive of the development of a new sharing and benefits system to support adequate and fair sharing of benefits, and was committed to working with African partners to develop such a system.

    The United Kingdom published multi-dimensional poverty measures annually. The Government’s priority was to grow the economy, as this was the best way to improve living standards. To achieve growth, decisions on tax and spending needed to be balanced. 

    Questions by a Committee Expert

    LAURA CRACIUNEAN-TATU, Committee Chair and Taskforce Member of the United Kingdom, said in England and Wales, the attainment gaps in education were widening, with inadequate measures to address them.  In Scotland, the new bill on education had been criticised as it failed to address urgent needs, and there were high levels of bullying in school, including incidents of misogyny and racism.  There were also major issues of bullying in Northern Ireland, including cyberbullying, on the grounds of race, sexual orientation, gender identity or sex characteristics, disability, migration or other status.  Traveller and Roma children had some of the lowest levels of educational attainment.  Acts including the Special Needs Disability Act 2016 and the Integrated Education Act 2022 had not been fully implemented.  For Jersey, measures to address the poverty-related attainment gap were inefficient, and the Jersey premium had limited impact. 

    What measures had been implemented to address these challenges, and what were the concrete results? How were they evaluated in terms of impact and implementation?  How was it ensured that all educators were trained on bullying and what targeted measures were in place to address this issue?  Did children of migrant families have access to education, including language support, uniform grants, school meals and school transport?  How was it ensured that Traveller and Roma children remained in the educational system?  In Northern Ireland, there were currently 72 integrated schools; was there a plan to increase this number?  Was there any evaluation of the impact of the Jersey premium in reducing the attainment gap?  Were there any plans to address legislation to balance between the right to light work and the full benefit of education for children?

    Had the Irish Language Commissioner been appointed?  What measures were in place to ensure that the arts sector in all jurisdictions received sufficient, secure, long-term funding proportional to inflation, and that the right to take part in cultural life was not affected by the cost-of-living increases?  What measures were in place to ensure access to sport for transgender persons and persons with disabilities?

    Could information be provided on the status of the proposed Northern Ireland Troubles (Legacy and Reconciliation) Bill and how it would contribute to fostering intercultural dialogue and reconciliation?

    Responses by the Delegation

    The delegation said last year, a proposal for a draft remedial order was introduced into the United Kingdom parliament, as the first step to repeal and replace the Legacy Act. 

    The Government wanted to see more people engaging in physical activity, and that included transgender persons.  A different approach was required in competitive sport, where the Government had a responsibility to protect the integrity of women’s sport.  Each sport was different, and the Government worked with all sports organizations to prioritise integrity while also being inclusive.  For instance, tennis and golf had decided to protect the fairness of competition at the competitive level, but adopt a more inclusive approach at the recreational level. 

    Access to culture was a core part of the United Kingdom, and each part of the country had an Arts Council.  Much of the cultural offerings in the United Kingdom were free of charge, including entry to museums and free music tuition for children. 

    The Addressing Bullying in Schools Act in Northern Ireland commenced in 2021.  It put onus on schools to address the motivations of bullying and put policies in place at the school level.  Three new language authorities would be established with preparations at an advanced stage. 

    The Scottish Government published a cultural strategy in 2020 and a refreshed action plan to support delivery in 2023, responding to recent challenges including COVID-19 and the cost of living.  The Government had allocated more than 50 million pounds to cultural funding, which was an historic increase. 

    Wales had invested two million pounds in literacy programmes and 1.6 million pounds for science, technology, engineering and mathematics in schools.  In Wales, around 67 per cent of students attending mainstream schools could access a free school meal at lunchtime.  Tackling the impact of poverty in education was a priority. New guidance was published to help schools support Gypsy, Roma and Traveller students.  The school curriculum had been developed to be inclusive for all learners, with diversity as a cross-cutting theme.  Cardiff had been secured as the host of the Euro Games in 2027, which was a key event for lesbian, gay, bisexual, transgender and intersex persons. 

    Post COVID, the Government had established the Oak Academy, which had a specific focus on closing attainment gaps.  Teachers had reported positive outcomes when using Oak resources.  Local authorities were required to provide sufficient school places for the area.  No child could be denied schooling based on their ethnicity.  There was an active Gypsy and Roma stakeholder group which aimed to ensure that the barriers these young people faced were addressed. 

    Education Scotland had rolled out several programmes, including to address gender stereotypes, unconscious bias, and domestic abuse.  Numerous provisions had been put in place in Jersey to ensure equal education access for children from disadvantaged backgrounds. 

    Sport England had a 10-year plan to increase the participation of sport for persons with disabilities.  The overall investment figure into disability focused access was around 30 million pounds per year.  There had been 6.7 million pounds of investment directly to national disability sport organizations.  As a direct result of such investment, the United Kingdom took second place in the medal tally of the Paralympics last summer, which would inspire more people with disabilities to participate in sport. 

    Questions by Committee Experts

    JOO-YOUNG LEE, Committee Expert and Taskforce Member, asked what measures were in place to ensure children of pre-school age had access to affordable, quality childhood education?  The State party continued to treat social security as an instrument for getting people to work.  It was highly likely that if this approach continued, the State party would fail to address poverty.  Social security must be used to achieve an adequate standard of living for all people. 

    A Committee Expert asked to what extent corporal punishment at school was prohibited and sanctioned?  Was any form of corporal punishment against children treated as a criminal offence? What measures were being taken to implement anti-bullying plans? 

    JULIETA ROSSI, Committee Expert and Taskforce Member, asked how the State party was addressing the issue of stateless persons, particularly when it came to access to education and family reunification? 

    SEREE NONTHASOOT, Committee Expert and Taskforce Leader, said there were more than 80,000 children in foster care across the United Kingdom.  What was being done to close the attainment gaps in education for these children?  How was bullying prevented against lesbian, gay, bisexual, transgender and intersex students? 

    Responses by the Delegation

    The delegation said it was not correct that the Government considered social security just as a route to work.  Children’s early years were crucial to their development, health and life chances, and the Government aimed to set every child up to have the best start in life. 

    The Home Office Stateless Policy was designed to assist those who were not recognised as a citizen of any country.  This provided a means for stateless persons in the United Kingdom to access their basic human rights. 

    All forms of physical punishment of children were against the law in Scotland in all settings. An Act was passed in 2019 which removed the defence of “reasonable chastisement” to the existing offence of assault. 

    Closing Remarks

    SEREE NONTHASOOT, Committee Expert and Taskforce Leader, extended appreciation to the United Kingdom delegation for its superb time and sequence management, which allowed the Committee to raise all relevant questions.  The State party should implement robust legislative programmes and ensure people were confident that they would be protected at the international level.  The Committee implored the United Kingdom to ensure that all Crown Dependencies and Overseas Territories under its control provided the highest standard of human rights to everyone.  Mr. Nonthasoot thanked all those who had made the dialogue possible. 

    ROBERT LINHAM, Deputy Director, Rights Policy, Ministry of Justice of the United Kingdom and head of the delegation, said the dialogue had been rich and detailed, covering a variety of issues.  It was hoped that the Committee could see the efforts being undertaken in the whole of the United Kingdom to improve economic, social and cultural rights. The United Kingdom was a great supporter in the work of the treaty bodies and it was hoped this was evident through the dialogue.  Mr. Linham thanked everyone who had supported the dialogue. 

     

     

    Produced by the United Nations Information Service in Geneva for use of the media; 
    not an official record. English and French versions of our releases are different as they are the product of two separate coverage teams that work independently.

     

     

    CESCR25.004E

    MIL OSI United Nations News

  • MIL-OSI Asia-Pac: Nationwide celebration of Animal Husbandry and Animal Welfare Awareness Month extended till 13th March 2025

    Source: Government of India

    Nationwide celebration of Animal Husbandry and Animal Welfare Awareness Month extended till 13th March 2025

    Prof. S.P.Singh Baghel interacts with over 23000 Stakeholders from the Livestock Sector; Emphasizes on Sustainable Practices & Expanding Employment Opportunities

    Workshops, Health Camps, Vaccination Drives & Awards Aim to Educate Stakeholders; Improve Rural Prosperity and Economic Resilience

    Posted On: 14 FEB 2025 8:34PM by PIB Delhi

    Animal Husbandry and Animal Welfare Awareness Month celebration by the Department of Animal Husbandry and Dairying (DAHD) under the Ministry of Fisheries, Animal Husbandry and Dairying, has been extended until 13th March 2025 in its inaugural year to maximize outreach and impact. This initiative was started from 14th January 2025 wherein nationwide activities were organised by the department of animal husbandry and dairying in association with state animal husbandry and welfare departments that was earlier slated till 13th February 2025. In order to further promote and give boost to ethical animal husbandry practices, animal health and welfare in India, the awareness campaign will now be continued till 13th March 2025 across the country. To support the campaign, DAHD has also developed a dedicated dashboard for tracking and uploading all extension activities across the country. To mark the occasion, the Department organized an online webinar on 14th February, graced by the esteemed presence of Prof. S. P. Singh Baghel, Union Minister of State for Fisheries, Animal Husbandry & Dairying, and Panchayati Raj. The webinar witnessed an overwhelming response, with over 23,000 participants, including representatives from State Animal Husbandry Departments, veterinarians, para-veterinarians, Pashu Sakhis, farmers, and livestock rearers, joining via YouTube and Webex platforms.

    Addressing the participants, Prof. Baghel highlighted the critical role of the livestock sector in food security, employment generation, and economic growth. He emphasized that millions of farmers, especially in rural areas, depend on livestock for milk, meat, eggs, wool, and leather, as well as for manure to enrich crop production.  He highlighted that strengthening the livestock sector, directly contributes to rural prosperity and national economic resilience. Prof. Baghel reaffirmed the government’s commitment towards prioritizing animal husbandry within the rural development agenda, with DAHD working closely with State Animal Husbandry Departments to enhance livestock productivity, disease control, and the well-being of those engaged in the animal husbandry sector. He also emphasized the need to promote sustainable practices, improve animal care, and expand employment opportunities for farmers through various schemes and initiatives.

    The Union Minister of State placed special focus on the use of sex-sorted semen, stating that this innovation will help address the issue of stray cattle by ensuring more female calf births. He expressed confidence that with this technology, every household could have three female calves within the next five years. Additionally, he stressed upon the importance of expanding Artificial Insemination coverage to boost productivity, encouraging the use of IVF techniques for rapid breed improvement, and ensuring 100 percent vaccination coverage. He reiterated the government’s vision for an FMD-free India as part of Prime Minister Shri Narendra Modi’s goal for a disease-free livestock sector. He urged that knowledge of best animal husbandry practices and government schemes should reach even the most remote villages and pastoral communities.

    In her address,  Smt. Alka Upadhyaya, Secretary, DAHD, emphasized that annual observance of this campaign will help stakeholders adopt and implement good animal husbandry practices, promoting sustainable livestock management with a strong focus on animal welfare, productivity, and environmental responsibility. She also highlighted key government initiatives in the sector, such as the Rashtriya Gokul Mission, National Livestock Mission, Livestock Health and Disease Control Programme and the ongoing Livestock Census.

    As part of the campaign, States are actively organizing workshops and webinars to educate farmers and stakeholders, health and infertility camps to enhance livestock well-being, deworming and vaccination drives to prevent diseases, awareness camps, cattle exhibitions, and best livestock farmer awards. Photography, essay writing, and art competitions are being held in schools and colleges, while walkathons, dog shows, and horse shows have engaged the public to spread awareness about animal health and welfare. Television and radio broadcasts have promoted animal husbandry schemes, with pamphlets and brochures being distributed to improve public outreach.  The department is also undertaking social media campaigns to share best practices and the economic benefits of animal husbandry. The Animal Husbandry and Animal Welfare Awareness Month campaign is a major step towards empowering farmers, promoting scientific livestock management, and enhancing economic returns. By fostering widespread adoption of modern practices and government schemes, this initiative will play a crucial role in improving animal health, increasing productivity, and ultimately boosting farmers’ incomes.

    ****

    Aditi Agrawal

    (Release ID: 2103396) Visitor Counter : 12

    MIL OSI Asia Pacific News

  • MIL-OSI Australia: European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

    Source: CLS Limited

    European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

    – KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional mRNA COVID-19 vaccines in clinical trials

    WALTHAM, Mass. and SAN DIEGO, Feb. 14, 2025 /PRNewswire/ — Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) and sa-mRNA pioneer Arcturus Therapeutics (Nasdaq: ARCT) today announced that the European Commission has granted marketing authorization for KOSTAIVE ® (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for individuals 18 years and older. KOSTAIVE is the first sa-mRNA COVID-19 vaccine to receive approval from the European Commission (EC). KOSTAIVE is currently marketed in Japan against COVID-19.

    The European Commission approval follows a positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) on December 12, 2024. The centralized marketing authorization of KOSTAIVE is valid in all EU member states and in the EEA countries.

    “The European Commission’s approval marks a significant milestone in our ongoing development program for KOSTAIVE,” said Jonathan Edelman, MD, Senior Vice President of the Vaccines Innovation Unit, CSL. “We are actively working to optimize KOSTAIVE’s formulation to better meet the needs of healthcare professionals and their patients. As COVID-19 remains an unpredictable global threat, CSL is dedicated to completing these technical enhancements and making this innovative vaccine available in Europe as soon as possible.”

    The approval is based on positive clinical data from several studies, including an integrated phase 1/2/3 study demonstrating KOSTAIVE’s efficacy and tolerability, and Phase 3 COVID-19 booster trials, which achieved higher immunogenicity results compared to a conventional mRNA COVID-19 vaccine comparator. A follow-up analysis evaluating a booster dose of KOSTAIVE also showed that the vaccine elicited superior immunogenicity and antibody persistence for up to 12 months post-vaccination against multiple SARS-CoV-2 strains in both younger and older adult age groups versus the same mRNA comparator.

    “KOSTAIVE and sa-mRNA technology signify a major advancement in vaccine innovation, providing the potential for broader and more enduring protection,” said Joseph Payne, CEO of Arcturus. “This approval highlights the clinical promise of KOSTAIVE and its ability to protect against the ever-changing COVID-19 virus.”

    About sa-mRNA
    mRNA vaccines help protect against infectious diseases by providing a blueprint for cells in the body to make a protein to help our immune systems recognize and fight the disease. Unlike standard mRNA vaccines, self-amplifying mRNA vaccines instruct the body to make more mRNA and protein to boost the immune response.

    About CSL
    CSL (ASX: CSL; USOTC: CSLLY) is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSLBehring.com/Vita and follow us on Twitter.com/CSL

    For more information about CSL, visit www.CSL.com.

    About Arcturus
    Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

    Forward-Looking Statements
    This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, are forward-looking statements, including those regarding strategy, future operations, the likelihood of success (including safety, efficacy and commercialization) of KOSTAIVE, the likelihood that clinical results received to date will be predictive of future clinical results of protection against changing virus variants, the likelihood of optimizing KOSTAIVE’s formulation and completing technical enhancements, and the impact of general business and economic conditions. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements, including those discussed under the heading “Risk Factors” in Arcturus’ most recent Annual Report on Form 10-K, and in subsequent filings with, or submissions to, the SEC, which are available on the SEC’s website at www.sec.gov. Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

    CSL Media Contacts:
    Sue Thorn, CSL
    Mobile : +1 617-799-3151 
    Email: Sue.Thorn@cslbehring.com

    Em Dekonor, CSL Seqirus
    Mobile: +44 (0)7920500496
    Email: Emmanuella.Dekonor@seqirus.com

    In Australia:
    Jimmy Baker, CSL
    Mobile: +61 450 909 211
    Email: Jimmy.Baker@csl.com.au

    Investor Inquiries:
    Chris Cooper, CSL
    Mobile: +61 455 022 740
    Email:  Chris.Cooper@csl.com.au

    Arcturus Media Contact: 
    Public Relations & Investor Relations 
    Neda Safarzadeh 
    VP, Head of IR/PR/Marketing 
    (858) 900-2682 
    IR@ArcturusRx.com

    SOURCE CSL

    MIL OSI News

  • MIL-OSI: Year-end Report – January-December 2024

    Source: GlobeNewswire (MIL-OSI)

    STOCKHOLM – 14 February 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report January-December 2024. The full report is available on the Company’s website.

    “Stronger liquidity will ensure our ongoing ability to continue advancing the portfolio companies who are at earlier stages in the development phase and offer the potential for creating substantial value going forward”, says Viktor Drvota, CEO, Karolinska Development.

    Significant events during the fourth quarter

    • The portfolio company Umecrine Cognition presented new preclinical data on golexanolone, showing retained dopamine signaling in Parkinson’s disease, at the 10th International Conference on Neurology and Brain Disorders 2024 in Baltimore, Maryland, US (October 2024).
    • The portfolio company SVF Vaccines, presented positive clinical safety and immunogenicity data from a clinical phase 1 study of the universal Covid-19 vaccine candidate, SVF-002 (October 2024).
    • The portfolio company BOOST Pharma successfully completed a pre-IND meeting with the U.S. Food and Drug Administration, FDA, for its cell therapy aiming to treat children with the rare bone disease Osteogenesis Imperfecta (OI). The positive outcome from the meeting triggered the second tranche of previously agreed investment from Karolinska Development (November 2024).
    • Karolinska Development’s Extra General Shareholders’ Meeting on 13 November 2024 decided, among other things, to elect Will Zeng, with the dismissal of the current director Theresa Tse, as a new director of the Board of Directors. The current directors Hans Wigzell, Anna Lefevre Skjöldebrand, Benjamin Toogood and Philip Duong remain as directors of the Board of Directors and Hans Wigzell remains as chairperson (November 2024).
    • The portfolio company SVF Vaccines appointed Dr Gaston Picchio as acting CEO. He will assume the position with effect from November 15th, as Dr Richard Bethell decided to step down as CEO to pursue other professional interests while remaining associated with the company in an advisory role (November 2024).
    • The portfolio company Umecrine Cognition presented data from a recent interim analysis from an ongoing Phase 1b/2a clinical study of golexanolone in patients with Primary Biliary Cholangitis. The preliminary results show that golexanolone was well-tolerated and achieved drug exposure levels that correlate to clinical treatment doses. The results were presented at the Late Breaking Poster session at the American Association for the Study of Liver Diseases’ (AALSD) 75th Liver Meeting, in San Diego, CA, USA, on November 18, 2024 (November 2024).
    • The portfolio company Modus Therapeutics secured access to bridge financing of up to SEK 5 million from Karolinska Development, the company’s largest shareholder. The funding enabled Modus to initiate the recently approved phase 2a study in chronic kidney disease (November 2024).
    • Karolinska Development announced that the company has decided to implement organizational changes in order to reduce the cost base of its operations. The changes involve reducing the management team by one person and giving notice of redundancy to a total of three employees. This is estimated to reduce the company’s personnel costs by approximately 20 percent (December 2024).
    • The portfolio company, Modus Therapeutics, dosed the first patient in a phase 2 clinical study of the drug candidate sevuparin, evaluated as a treatment for chronic kidney disease with anemia. The study is being conducted at Centro Ricerche Cliniche di Verona in Italy (December 2024).
    • Karolinska Development divested 4,6 million shares in the portfolio company OssDsign and thereby strengthened the investment company’s liquidity. Karolinska Development holds nearly 5 million shares in OssDisgn after the divestment (December 2024).
    • Karolinska Development announced that the company’s Chairman of the Board, Professor Hans Wigzell, has decided to resign from his position. The Board of Directors of Karolinska Development appointed Ben Toogood as new Chairman until the next General Shareholders’ Meeting (December 2024).
    • The portfolio company Umecrine Cognition raised SEK 23.8 million through a convertible loan to be used for the continuation of the company’s clinical study of golexanolone in primary biliary cholangitis. The convertible loan with attached share options is directed to a consortium of investors (December 2024).

    Significant post-period events

    • The portfolio company AnaCardio secured SEK 205 million in a series A extension financing round and reported positive results from the first part of a Phase 1b/2a study of AC01 in patients with heart failure and reduced ejection fraction. The final part of the study (phase 2a) is expected to start during the first quarter of 2025 (January 2025).
    • The portfolio company Dilafor announced that it successfully completed regulatory meetings with the U.S. Food and Drug Administration, FDA, and European Health Agencies, regarding the continued development of the company’s drug candidate tafoxiparin. The completed meetings mark the end of a comprehensive dialogue with regulatory authorities in the US and EU to reach an alignment between the authorities on designing pivotal clinical Phase 3 studies in Europe and the US to evaluate tafoxiparin as a new potential treatment for priming of labor (January 2025).

    Financial update fourth quarter

    • The net profit/loss for the fourth quarter was SEK 18.6 million (SEK -1,9 million in the fourth quarter of 2023). Earnings per share totaled SEK 0.1 (SEK -0.01 in the fourth quarter of 2023).
    • The result of the Change in fair value of shares in portfolio companies for the fourth quarter amounted to SEK 18.7 million (SEK 6.6 million in the fourth quarter of 2023). The result is mainly the effect of the upturn in share price in the listed holdings OssDsign and Modus Therapeutics and also by an increase in value in AnaCardio in connection with the investment round. The upturn was partly offset by a downturn in the share price in the listed holdings.
    • The total fair value of the portfolio was SEK 1,451.5 million at the end of December 2024, corresponding to a decrease of SEK 11.6 million from SEK 1,463.1 million at the end of the previous quarter. The net portfolio fair value at the end of December 2024 was SEK 1,120.8 million, corresponding to a decrease of SEK 1.0 million from SEK 1,121.8 million at the end of the previous quarter. The main reason for the net decrease in fair value was the partial divestment of OssDsign and the downturn in the share price of the listed holding Promimic. The decrease was partially offset by the increase in the price of the listed holdings OssDsign and Modus Therapeutics together with the increase in value of AnaCardio in connection with the investment round. The quarter’s investments in Umecrine Cognition and BOOST Pharma also contributed to the increase in fair value.
    • Net asset value amounted to SEK 1,245.0 million, per share SEK 4.6, at the end of December 2024 (SEK 1,253.4 million, per share SEK 4.6 at the end of December 2023).
    • Net sales totaled SEK 0.5 million during the fourth quarter of 2024 (SEK 0.5 million during the fourth quarter of 2023).
    • Karolinska Development invested a total of SEK 19.4 million in portfolio companies during the fourth quarter of 2024 (SEK 41.6 million in the fourth quarter of 2023). Fourth quarter 2024 investments in portfolio companies by Karolinska Development and other specialized life sciences investors totaled SEK 155.7 million (SEK 125.3 million in the fourth quarter of 2023).
    • Cash and cash equivalents increased by SEK 12.7 million during the fourth quarter, totaling SEK 52.0 million on 31 December 2024 (SEK 85.3 million on 31 December 2023).

    Financial update full-year

    • The full-year net profit/loss was SEK -8.1 million (SEK 5.4 million in 2023). Earnings per share totaled SEK -0.03 (SEK 0.02 in 2023).
    • The full-year result for the change in the fair value of the portfolio amounted to SEK 1.6 million (SEK 15.2 million during 2023).
    • The total fair value of the portfolio was SEK 1,451.5 million at the end of December 2024, an increase from SEK 1,440.3 million at the corresponding date in 2023. The net portfolio fair value was SEK 1,120.8 million, an increase by SEK 10.5 million from SEK 1 110.3 million at the corresponding date in 2023.
    • Net asset value amounted to SEK 1,245.0 million, per share SEK 4.6, at the end of December 2024 (SEK 1,253.4 million, per share SEK 4.6 at the end of December 2023).
    • Revenue totalled SEK 1.8 million for the full-year of 2024 (SEK 2.0 million in 2023).
    • Karolinska Development invested a total of SEK 62.0 (103.0) million in its portfolio companies during the full-year. Full-year investments in the portfolio companies by Karolinska Development and other specialised life sciences investors totalled SEK 490.3 (394.5) million.
    • Karolinska Development’s cash compensation from sold shares and earn-out agreements regarding divested portfolio companies amounted to SEK 42.4 (18.3) million during the year.
    • Cash and cash equivalents decreased by SEK 43.3 million during the full-year, totalling SEK 42.0 (85.5) million on 31 December 2024.
    • The Board does not propose any dividend for the financial year 2024.

    The Year-end Report for Karolinska Development AB for the period January-December 2024 is available as a PDF at www.karolinskadevelopment.com.

    For further information, please contact:

    Viktor Drvota, CEO, Karolinska Development AB
    Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

    Hans Christopher “HC” Toll, CFO, Karolinska Development AB        
    Phone: +46 70 717 00 41, e-mail: hc.toll@karolinskadevelopment.com

    TO THE EDITORS

    About Karolinska Development AB

    Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients’ lives while providing an attractive return on investment to shareholders.

    Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

    Karolinska Development has established a portfolio of eleven companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

    The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

    For more information, please visit www.karolinskadevelopment.com

    Attachments

    The MIL Network

  • MIL-Evening Report: In Robert F. Kennedy Jr, the US has put a conspiracy theorist in charge of public health

    Source: The Conversation (Au and NZ) – By Hassan Vally, Associate Professor, Epidemiology, Deakin University

    Overnight, Robert F. Kennedy Jr was confirmed as the secretary of the US Health and Human Services Department. Put simply, this makes him the most influential figure in overseeing the health and wellbeing of more than 330 million Americans.

    As health secretary, Kennedy will be involved in overseeing federal health agencies that regulate medical research, disease prevention, drug approvals and health-care programs.

    This includes oversight of the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration and the National Institutes of Health, which are among the most crucial public health agencies in the country.

    Reports suggest he’ll oversee a budget in the order of US$1.8 trillion (A$2.8 trillion) annually.

    In the era of Trump 2.0, there’s little that shocks me anymore. But Kennedy would have to be the most unqualified person ever to hold this crucial role of protecting the health of the American people.

    A history of discounting science

    The absolute minimum requirement for someone occupying such as role should be an understanding of science and respect for scientific evidence and expertise. Yet, Kennedy fails spectacularly in this regard.

    Here are just some of the false claims he has made over the years:

    None of these positions has even the smallest amount of scientific support.

    It’s hard to predict what Kennedy will do as health secretary, especially given his confirmation hearings looked to be an exercise in being vague, evasive and denying or downplaying his prior controversial statements to secure support.

    But there are three areas where his views are fairly clear and his appointment could be expected to have a significant impact. These are water fluoridation, infectious diseases research and vaccines.

    Fluoridation of water

    Kennedy has been a long-term opponent of water fluoridation, despite its proven benefits in preventing tooth decay. He has consistently questioned its safety and claimed it’s linked to a range of illnesses such as arthritis, bone cancer, IQ loss and neurodevelopmental disorders.

    While a recent review suggested a link between water fluoridation and lower IQ in children, the levels of fluoride in the water in countries included in this review were generally several times higher than the levels in public water fluoridation programs in countries such as the US and Australia. There were also other limitations that make interpreting these findings challenging.

    The CDC has identified community water fluoridation as as one of the ten great public health achievements of the 20th century. And it continues to benefit dental health today, without any convincing evidence of possible harms.

    Nonetheless, it seems likely that in keeping with his longstanding views one of Kennedy’s first priorities will be to try to halt water fluoridation in the US.

    Infectious diseases

    Alongside his confirmation as health secretary, US President Donald Trump signed an executive order establishing “The President’s Commission to Make America Healthy Again”, with Kennedy as the chair.

    The Make America Healthy Again movement (MAHA) is an initiative driven by Kennedy focusing on improving nutrition, increasing transparency in medical practices and reducing the corporate influence in health.

    Though premised primarily on combating chronic diseases, the movement also embraces scepticism of established medical practices, unproven alternative therapies and a general mistrust of institutions.

    What’s more, Kennedy’s focus on chronic diseases seems to be coming at the expense of continued work on infectious diseases.

    He has proposed directing the National Institutes of Health to pause infectious disease research for eight years to prioritise research into chronic diseases and alternative treatments.

    As health secretary, Kennedy has the power to shift research priorities. If he were to effectively halt infectious diseases research – in the wake of COVID and with a looming threat of future pandemics – this would be catastrophic for the US and global health.

    Vaccine scepticism

    Related to infectious diseases, there’s little doubt the area in which Kennedy has done the most damage relates to vaccines.

    He has dedicated a large part of his life to undermining public confidence in vaccines. This is despite overwhelming scientific evidence demonstrating their safety and effectiveness, and the millions of lives they’ve saved.

    Although he has subsequently denied it, Kennedy is on record as falsely stating there is no such thing as a safe and effective vaccine. Notably, he has continued to push the debunked claim that the measles, mumps and rubella (MMR) vaccine is linked to autism, despite the single study finding this having been widely discredited.

    Kennedy’s frequent assertion that he’s not anti-vaccine, but “pro-safety”, is also deeply disingenuous. Being “pro-safety” is a deliberately vague notion designed to appear reasonable while at the same time undermining the scientific evidence.

    The impact of Kennedy’s appointment as health secretary on vaccine confidence will not just be limited to the US. Vaccine hesitancy has been recognised as one of the greatest threats to public health. Having a vaccine sceptic leading the US health agencies has the potential to harm vaccine uptake worldwide.

    As we’ve seen during the COVID pandemic, producing a vaccine is only half the battle. Convincing people to take it is just as important. There’s no doubt Kennedy’s influence on public health messaging could further erode vaccine confidence at a time when vaccine messaging must be clear.

    It’s bad news for the US and the world

    One of the reasons Kennedy poses such a threat to public health in the US and globally is his lack of trust in science. He believes a narrative can be crafted by picking and choosing any study that fits with his world view, regardless of its quality.

    In addition, he personifies the bad-faith tactics of conspiracy theorists globally, “selling” the flawed premise that any assertion is valid until others prove it false.

    What the world needs now is a safe pair of hands leading public health in the US. Someone who is guided by evidence – not someone who promotes anti-science propaganda and conspiracy theories.

    Hassan Vally does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

    ref. In Robert F. Kennedy Jr, the US has put a conspiracy theorist in charge of public health – https://theconversation.com/in-robert-f-kennedy-jr-the-us-has-put-a-conspiracy-theorist-in-charge-of-public-health-249601

    MIL OSI AnalysisEveningReport.nz

  • MIL-OSI United Kingdom: Impact of new RSV vaccine

    Source: Scottish Government

    Report shows fewer older people hospitalised.

    Health Secretary Neil Gray has welcomed a report showing the new RSV (Respiratory Syncytial Virus) vaccine has led to a significant decrease in hospitalisations among older people.

    Public Health Scotland (PHS) research, published in The Lancet Infectious Diseases Journal, demonstrates that vaccination resulted in a 62% reduction in RSV-related hospitalisations among the eligible 75-79 age group.

    The Scottish Government invested £4.2 million via health boards in the vaccine supply. The programme began last August following expert scientific advice from the Joint Committee on Vaccination and Immunisation (JCVI).

    Mr Gray said:

    “Once again we see evidence of the role which vaccinations play in preventing serious illness and keeping people out of hospital.

    “We were pleased to be the first nation in the UK to introduce the new RSV vaccine in time to maximise the benefit to the more vulnerable ahead of winter. This research demonstrates just how many people avoided ending up in hospital as a result.

    “RSV can be very serious for older adults, newborns and infants – potentially causing lung disease such as pneumonia.

    “It is encouraging to see that by the end of November, 68% of eligible older adults had received their vaccinations and I’d urge all those eligible to come forward for their vaccine when called. It is incredibly important for older adults and pregnant women to protect their newborn babies from RSV.”

    Background

    RSV vaccine during pregnancy | NHS inform

    RSV vaccine for adults | NHS inform 

    The RSV programme was in addition to winter vaccines offered, such as flu, Covid-19 and pneumococcal.

    MIL OSI United Kingdom

  • MIL-OSI USA: VIDEO: Senator Peters Takes to Senate Floor to Oppose Nomination of Robert F. Kennedy Jr. for Secretary of Health and Human Services

    US Senate News:

    Source: United States Senator for Michigan Gary Peters
    WASHINGTON, D.C. – U.S. Senator Gary Peters (MI) spoke on the Senate floor in opposition to the nomination of Robert F. Kennedy Jr. to serve as Secretary of the Department of Health and Human Services (HHS). Peters underscored his concerns over Kennedy’s severe lack of qualifications for the critical position, given the fact that, if confirmed, Kennedy would be tasked with managing federal programs that millions of Americans depend on every day, including Medicare and Medicaid, and agencies such as the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), National Institutes of Health (NIH), and other agencies that prepare for and respond to public health and medical emergencies. Following his remarks, Peters voted against Kennedy’s nomination.
    “Throughout his entire nomination process, it has become clear that Mr. Kennedy is wholly unprepared to lead this Department,” said Senator Peters. “Mr. Kennedy’s lack of experience and basic understanding of our nation’s health care system is, to say the least, extremely alarming. We cannot confirm a nominee who doesn’t even know the most basic answers about programs that he’s actually in charge of administering.” 
    Peters continued, “We need a Secretary who will protect the health of Americans. Robert Kennedy is not that Secretary. And if he is confirmed to lead the Department of Health and Human Services, the American people will ultimately pay the price with their health.”

    To watch a video clip of Senator Peters’ remarks, click here.
    During his remarks, Peters highlighted concerns that Michiganders from across the state shared with his office over Kennedy’s nomination:
    “Since Mr. Kennedy was nominated to lead HHS, I’ve heard from thousands of my constituents from every corner of Michigan, from densely populated cities to some of the most rural areas in our state, who are deeply concerned about how his plans for the department would impact families. For example, I’ve heard from countless folks about the rising cost of health care that is squeezing Michigan families’ budgets. Health care prices are rising faster than inflation, making it even harder for people to get the care that they need.
    “I’ve heard from a constituent who has operated a food pantry in her community for 13 years. She worries about what will happen to the people that she serves if they do not have access to the food security programs made possible by HHS.
    “I received a letter from a social worker in Michigan who helped students who were traumatized by the horrific shootings at Oxford High School in Michigan and Michigan State University. She is worried that, without proper mental health resources, Americans who have been impacted by senseless gun violence, whether at school, at their places of worship, at night clubs, or at shopping malls, they will grieve and struggle alone.
    “A Michigan scientist who specializes in CDC research contacted my office. They fear that if Mr. Kennedy is confirmed, it could impact their ability, and the ability of thousands of researchers all across our country, to conduct medical research that is literally saving lives.
    “A concerned mother wrote me and my office that when she was 38 weeks pregnant, she told me that Mr. Kennedy’s long history of spreading dangerous medical disinformation and undermining public health initiatives is directly at odds with how she plans to keep her future child from infectious disease.
    “I’ve even heard from parents who are concerned about Mr. Kennedy’s narrative suggesting vaccines cause autism. Because he has given credibility to these lies, and questioned facts from scientists and doctors, these parents worry that their children will not receive the most basic, routine care that they deserve.   
    “I also heard from a constituent who was born before the polio vaccine was approved. She said that, to this day, she can still remember the relief on her mother’s face when the polio vaccine became available. This moment has stuck with her throughout her 30-year career as a registered nurse, where she has made it her life’s work to study and safely administer vaccines in her community.” 
    “And let’s be clear. Let’s be absolutely clear. Vaccines are scientifically proven to protect against diseases like chickenpox, polio, influenza, and yes, COVID-19.”

    MIL OSI USA News

  • MIL-OSI USA: “He’s a Danger,” King Warns in Floor Speech Against RFK Jr. Nomination

    US Senate News:

    Source: United States Senator for Maine Angus King

    WASHINGTON, D.C.  U.S. Senator Angus King (I-ME) tonight took to the floor of the Senate to share his concern over President Trump’s nomination of Robert F. Kennedy, Jr. to serve as the Secretary of Health and Human Services (HHS). In the speech, Senator King began his remarks by outlining the roles of Congress and the Presidency as America’s Founders envisioned: to make laws and to execute laws, respectively.  He then turned to the HHS candidate, speaking to Kennedy’s lack of experience and qualifications needed to run a large-scale health organization, and pointed out Kennedy’s long held public opinions as hostile toward the mission of the agency. He also warned of Kennedy’s dangerous skepticism toward proven, life-saving vaccines, sharing a childhood memory of a classmate who had polio.

    “Mr. President, I’d like to begin my remarks this afternoon by talking a little bit about the Constitution. I spent some time last week talking about the Constitution and our failure to observe that the Constitutional, fundamental structure of the division of power between the Congress and the Executive is being violated and the Congress is allowing it to happen. Another provision of the Constitution is the provision in Article I about advise and consent. It’s a fundamental check and balance built into the Constitution by the framers for a reason. It wasn’t a throw-away line or a few sentences that were put in because they wanted to fill the paragraph out. Again, it’s part of the structure that was designed to protect us from tyranny. And the structure involved the division of power, the separation of power because the framers knew that if all power was concentrated in a single individual or single institution, that institution or that individual would inevitably abuse our people. That’s human nature. That’s 1,000 years of human nature. All power corrupts and absolute power corrupts absolutely. So, the advise and consent provision was in the Constitution for a reason. It was in there for a reason, in order to provide a check on the executive and the people who were going to be put in charge of running the administration. 

    “By the way, I want to stop for a minute and focus on the word administration and the word executive, because it really goes to the discussion we’re having in this country right now about how our government is supposed to work. The executive comes from the word execute, and the word execute means put into action. It doesn’t mean initiate the action. It means put it into action. The same for the term administration. There’s a reason we call it the administration. They are to administer the laws. In fact, the obligation on the president in Article II is to see that the laws are faithfully executed. And it does not give the president the power to ignore laws or to decide which laws he or she thinks are okay, to ignore the responsibility and constitutional authority of the congress to define spending. It does not give the president that power. Although, the fellow we approved for Office of Management and Budget last week thinks he has that power. Or this President or any president has that power. That’s absolutely antithetical to the Constitution, as established by the framers. So, administration means administer the laws, executive means execute the laws, not make them. We make the laws here and the administration is to faithfully execute those laws. 

    “Now, let’s talk about advise and consent. Advise and consent means we have a responsibility — a Constitutional responsibility to consider each of the president’s nominees for these important jobs. This isn’t something that we may do or occasionally do. This is a fundamental part of our job. We take an oath when we come here to defend the Constitution against all enemies, foreign and domestic. I think it’s interesting — they knew in 1787 that there was a potential for domestic enemies to the Constitution. So we have an obligation to take advise and consent seriously. 

    “Now, I’m a former governor, as is the presiding officer. And as a former executive, I believe the executive should have the ability to choose the team that they want, to choose their advisors. To choose the people they will work with, with some limitations. In other words, I start with the premise of the person elected should perhaps get the benefit of the doubt is a little too strong, but I start with the premise that they were elected and they should be able to choose the team that they are going to be working with. However, I think there are two qualifications. This has been my stated position on this since I entered the Senate. Benefit of the doubt to the executive, however, the nominee must be manifestly qualified and not hostile to the mission of the agency to which they’ve had been appointed. Two criteria that for me give life to the idea of advise and consent. 

    “Okay, let’s talk about Robert F. Kennedy, Jr. He, unfortunately, checks both of the boxes as to being disqualified. Number one, he’s not remotely qualified to run an organization. He has no experience running anything remotely like the scope and scale of the Department of Health and Human Services. No executive experience in that sense. So that’s number one. Is he qualified? No. He’s grossly unqualified. But the second box is he hostile to the mission of the agency? And if the mission of the agency, HHS, is to protect the health of the American people, I would argue he is manifestly hostile to that mission. There’s been a lot of discussion here today and I think it’s interesting. I haven’t heard too many people come up on the floor and support this nominee and tell us why he should be approved because, you know what, Mr. President? If this were a secret ballot, this man wouldn’t get 20 votes. Everybody in this body knows he’s not qualified. Everybody in this body knows he has no business anywhere near this position. But here we are. We’re going to take a vote. Unfortunately, it will probably be on a party-line basis. 

    “But let me focus on just one little piece. On January 29, barely a week ago, before the Senate Finance Committee, here’s what Mr. Kennedy said. Quote, “news reports have claimed that I’m antivaccine or anti-industry. I am neither. I am pro-safety. All of my kids are vaccinated.” I bet that came as news to all of the folks he’s been leading astray over the last 25-30 years. I believe vaccines have a critical role in health care. I am reminded of Saul on the road to Damascus. A miraculous conversion. A bright light was shown and suddenly the scales fell from his eyes in his confirmation hearing. Okay, let’s go back a little over a year, July 6, 2023, this is a quote, a direct quote, “there is no vaccine that is safe and effective.” He later said, on the same podcast, ‘vaccines are inherently unsafe.’ Mr. President, this man shouldn’t be confirmed because he told the committee and the Senate something diametrically opposed to the position he’s taken the last 30 years, all of his adult life. 

    “Maya Angelou said, “If somebody tells you who they are, you should believe them.” And he’s told us repeatedly. And he has acted on his vaccine skepticism. This wasn’t something that was rumbling around in his head. He’s traveled the world. He’s written articles, gone on podcasts, gone on TV and he’s discouraged people from being vaccinated. And now he has this miraculous conversion 10 days ago. ‘All my kids are vaccinated. I believe vaccines have a critical role in health care.’ The same thing during COVID. He said, ‘it is criminal medical malpractice to give a child one of these vaccines.’ Wow, criminal malpractice. And of course it’s been discussed. He said I do believe that autism does come from vaccines. July of 2023 there was one study in England — I think it was in 1998 — that showed that — purported to show a tenuous convection between vaccines and — connection between vaccines and autism. I’m reasonably confident that one of the authors recanted. It was withdrawn and it’s been debunked over and over and over again, but this man has been peddling this lie for 20 years, and who knows how many parents have fallen for that on the one hand who knows how many children have paid the price. Just to talk about vaccines, at one point during the pandemic, there was a survey — July of 2021 — remember, that was the height of it — they surveyed 50 hospitals in 17 states. 94% of the patients hospitalized in July of 2021 were unvaccinated. What does that tell you? Vaccinations worked. And people who were unvaccinated were at enormously higher risk. 94% of the people were unvaccinated.

    “In addition to the vaccination issue, this guy — this man doesn’t respect the FDA, the agency that was put in place to protect our health, to regulate us, to be sure that we’re getting safe medications, to deal with some of the awful problems of the potential of harmful medications literally getting into America’s bloodstream. In December of 2024, barely a couple months ago, he said he would fire officials at the FDA. And in October 2024 he said on X, ‘FDA’s war on public health is about to end. If you work for the FDA and are part of this corrupt work, two messages for you: prepare your records and pack your bags.’ He didn’t say a certain office in the FDA or a certain part of the FDA or maybe there was one provision, a part that he didn’t think was helpful. He said, if you work for the FDA, that’s everybody, preserve your records and pack your bags. 

    “This man is not only unqualified, he’s anti-qualified. He’s a danger. We have physicians in the Senate — I believe that the Hippocratic oath, do no harm, should apply to Senate votes. You should not be voting for somebody who you know is going to do harm to the public health. So this is really a kind of surreal debate because everybody in this chamber knows this man should not be Secretary of Health and Human Services. 

    “Now, I want to end with a personal story. One of the few advantages of being older is that you have a long memory. And in 1952 I was entering the third grade at Macarthur School in Alexander, Virginia. In my class was a kid named Butch. And he was horribly twisted into a wheelchair. I don’t think I’d ever seen a wheelchair when I was going into the third grade. He was there, and I’m not even going to say how many years later, but I can close my eyes and see Butch in that chair. Polio was what he had. He was in pain daily. He could barely make himself understood. His arms were crossed. His legs were bent grotesquely in the wheelchair. And three years later the Salk Vaccine began what turned out to be the elimination of Polio. Where would we be as a country if this man had been the head at that time it was HEW and somehow put a stop to this vaccine, which I believe he has said even the Polio vaccine should be rescinded, which has saved millions of lives around the world. Where would we be? I can’t escape the memory of that boy in that wheelchair. I can’t forget the memory of my parents not letting me go to the public swimming pool because of the fear of Polio. Not being able to go out in the summer and play because of the fear of Polio that stalked the land. The former Republican leader was a victim of Polio. Former President Franklin D. Roosevelt was a victim of Polio. It was the vaccine. And, Mr. President, I hope this place comes to its senses and rejects this surreal nomination. It would be probably be hard to find somebody less qualified to serve in this position. I believe that it will lead to damage to our country, to our health, to our children, and I urge my colleagues to vote no. If you vote yes, you’ll regret it. Thank you, Mr. President. I yield the floor.”

    Senator King has been continuously sounding the alarm on President Donald Trump’s existential threat to the Constitution: he declared that the proposal to halt all federal grant and loan disbursement was illegal and a direct assault on the Constitution. More recently, he joined 36 Senators in a letter to Secretary of State Marco Rubio, sharing the detrimental effects of  the Trump Administration’s dismantling of the U.S. Agency for International Development (USAID). He also joined fellow Senate Select Committee on Intelligence (SSCI) colleagues in writing a letter to the White House about the risks to national security by allowing unvetted Department of Government Efficiency (DOGE) staff and representatives to access classified and sensitive government materials. Last week, he spoke on the Senate floor to share his growing concerns over the Trump Administration’s largely unconstitutional and unprecedented overreach; in the speech he cited the Founding Fathers to add historical perspective to the decision facing the Senate, including the importance of the separation of powers.

    MIL OSI USA News

  • MIL-OSI New Zealand: Speech for the opening of Wakefield Hospital

    Source: New Zealand Government

    AcknowledgementsGood afternoon, everyone. Thank you for being here.It’s a pleasure to join you here today to officially open this beautiful facility at Wakefield Hospital.I’d like to acknowledge the Evolution Healthcare leadership team, and their esteemed guests here today including investors, and mana whenua.I’d also like to acknowledge: 

    Evolution Board Chair, Scott Pickering
    Group CEO, Simon Keating
    Chief Executive of Hospitals & Day Surgeries, Michael Quirke
    General Manager, Carole Kaffes
    Health New Zealand Deputy Chief Executive, Robyn Shearer
    Deputy Commissioner of Health New Zealand, Ken Whelan
    And the Kapa Haka group from South Wellington Intermediate School

    And finally, I would like to thank and acknowledge the staff and clinicians providing exceptional care to patients here at Wakefield and other providers across the Wellington region. 
    Health TargetsAs you’re all aware, improving our health system is one of this Government’s top priorities.Last year we announced an ambitious new direction for health, reinvigorating five health targets to ensure that all New Zealanders can access timely, quality healthcare.We all know that you cannot manage what you do not measure.It is only with clear, measurable targets that we can understand and improve the performance of the health system. Targets focus resources, attention, and accountability.Targets save lives.The five health targets are tightly focused on things that really matter: faster cancer treatment, increased childhood immunisation, shorter stays in EDs and shorter wait times for assessments and treatment.Achieving these targets will require a back-to-basics approach in our public system to make sure our hospitals and community health services work smoothly and efficiently as a system, enabling our greatest asset – our frontline health workers – to provide the best possible care.The health system continues to be under significant pressure, and there is always a demand for more money. I am proud of the record investment this Government has made in health, but we need to also ensure we get value for money.  Role of Private Hospital SectorMeeting those targets will require working in a more collaborative way, especially when it comes to reducing waitlists for elective treatment.When we left office in 2017, 97.3 percent of New Zealanders were getting elective surgeries within four months. When Labour left office, it had dropped to 62.1 percent. It will take time to turn this around, but it is a top priority of mine.Partnering with the private health sector is a key part of our plans to deliver for Kiwis. Aside from ensuring our public systems are working as efficiently as possible, we also need to consider how we can make best use of the capacity and expertise the private health sector can offer.Wakefield Hospital is a strong provider for the people in the Capital, Coast and Hutt Valley districts, as well as supporting referrals from out of the region with people travelling from as far afield as Waikato and the South Island.In the 23/24 financial year, Wakefield Hospital treated 450 patients on behalf of Capital, Coast and Hutt Valley, and along with Bowen and Royston hospitals, meant Evolution Healthcare was the largest private provider for outsourcing in the Central Region.It is great to be here to celebrated the redevelopment of this hospital today and to congratulate everyone who has worked to deliver this project. The new Wakefield development includes seven new operating theatres, specialist cardiology and surgical treatment capacity, a 37-bed inpatient ward with capacity to expand an additional 32 inpatient beds. All this will increase the opportunities to deliver more for the Wellington Region and to grow opportunities to work closely with Wellington Hospital to provide more services and improve patient outcomes.Looking forward, the goal must be to create a mutually beneficial partnership that supports the health system and provides greater certainty for the private health sector.A key part of the strategy is a nationally supported approach to planning and outsourcing, and longer-term contracts and agreements which will help ensure patients get the treatment they need in a timely manner. By standardising referral arrangements and focusing on jointly managing waitlists by using all available capacity more effectively, Health New Zealand can prevent unnecessary delays and ensure that patients are referred to the right provider at the right time.As Minister of Health, my focus is and always will be on improving patient outcomes. Patients will be my number one priority, ensuring they get the timely and quality care they need and deserve. ConclusionI want to again thank you for the opportunity to join you here this afternoon, and for your ongoing dedication and investment into caring for New Zealanders. Congratulations to everyone who has been part of delivering this project, and to those who will be ensuring it delivers timely and quality care for patients in the Wellington Region. 

    MIL OSI New Zealand News